{"content":"<li class=\"n-box-item date-title\" data-end=\"1508299199\" data-start=\"1508212800\" data-txt=\"Monday, December 23, 2019\">Tuesday, October 17, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3301662\" data-ts=\"1508278120\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INO\" target=\"_blank\">INO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301662-inovio-pharmaceuticalsplus-2_6-rbc-starts-outperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Inovio Pharmaceuticals +2.6% as RBC starts at Outperform</a></h4><ul>   <li>Inovio Pharmaceuticals (<a href=\"http://seekingalpha.com/symbol/INO\" target=\"_blank\">INO</a> <font color='green'>+0.5%</font>) is on the move after hours, <font color='green'>up 2.6%</font>, after RBC opened coverage at Outperform on some enthusiasm around the company's treatment for cervical pre-cancers.</li>    <li>VGX-3100 could become the first such nonsurgical treatment, analyst Matthew Eckler says, and successful early trials could mean \"big upside.\"</li>    <li>RBC joins a half-dozen other firms with coverage, all in the Buy column.</li>    <li>Messner has a price target of $11, implying 76% upside from today's closing price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301662\" data-linked=\"Inovio Pharmaceuticals +2.6% as RBC starts at Outperform\" data-tweet=\"$INO - Inovio Pharmaceuticals +2.6% as RBC starts at Outperform https://seekingalpha.com/news/3301662-inovio-pharmaceuticalsplus-2_6-rbc-starts-outperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3301662-inovio-pharmaceuticalsplus-2_6-rbc-starts-outperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301658\" data-ts=\"1508277219\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOBL\" target=\"_blank\">MOBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301658-mobileironminus-10-after-naming-new-ceo-offering-preliminary-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MobileIron -10% after naming new CEO, offering preliminary Q3 results</a></h4><ul>     <li>MobileIron (NASDAQ:<a href='https://seekingalpha.com/symbol/MOBL' title='MobileIron, Inc.'>MOBL</a>) <font color='red'>-10.5%</font> after-hours on news that President and CEO Barry Mainz is <a href=\"https://seekingalpha.com/pr/16971334-mobileiron-announces-leadership-transition-accelerate-growth-profitability\" target=\"_blank\">leaving the company</a>, effective immediately, to be replaced by CFO Simon Biddiscombe; VP of Finance Shawn Ayers will serve as interim CFO.</li>     <li>Biddiscombe has served as CFO since 2015 and previously was CFO of ServiceSource International and President and CEO of QLogic during 2010-13.</li>     <li>MOBL also issued below-consensus Q3 revenue guidance of $42M-443M, vs, $45.1M analyst consensus estimate, with expected gross billings of $49.5M-$50.5M, which represents Y/Y growth of 5%-7%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301658\" data-linked=\"MobileIron -10% after naming new CEO, offering preliminary Q3 results\" data-tweet=\"$MOBL - MobileIron -10% after naming new CEO, offering preliminary Q3 results https://seekingalpha.com/news/3301658-mobileironminus-10-after-naming-new-ceo-offering-preliminary-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3301658-mobileironminus-10-after-naming-new-ceo-offering-preliminary-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301655\" data-ts=\"1508276133\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301655-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/HCLP' title='Hi-Crush Partners LP'>HCLP</a> <font color='green'>+10.6%</font>. <a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a> <font color='green'>+5.0%</font>. <a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a> <font color='green'>+3.4%</font>. <a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a> <font color='green'>+2.6%</font>. <a href='https://seekingalpha.com/symbol/SLCA' title='U.S. Silica'>SLCA</a> <font color='green'>+2.2%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/MOBL' title='MobileIron, Inc.'>MOBL</a> <font color='red'>-10.5%</font>. SCSS <font color='red'>-4.5%</font>. <a href='https://seekingalpha.com/symbol/CREE' title='Cree, Inc.'>CREE</a> <font color='red'>-2.3%</font>. <a href='https://seekingalpha.com/symbol/VSAR-OLD' title='Versartis, Inc.'>VSAR-OLD</a> <font color='red'>-1.9%</font>. <a href='https://seekingalpha.com/symbol/TRVG' title='Trivago'>TRVG</a> <font color='red'>-1.9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301655\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$HCR $IBM $INO - After Hours Gainers / Losers https://seekingalpha.com/news/3301655-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3301655-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301650\" data-ts=\"1508275381\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LRCX\" target=\"_blank\">LRCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301650-lam-research-reports-q4-guidance-beats-shipments-dropped-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lam Research reports Q4, guidance beats but Shipments dropped 6%</a></h4><ul>     <li>Lam Research (NASDAQ:<a href='https://seekingalpha.com/symbol/LRCX' title='Lam Research Corporation'>LRCX</a>) shares are <font color='red'>down 0.8%</font> aftermarket following Q4 results that beat EPS and revenue estimates.</li>     <li>Q1 guidance: Shipments, $2.5B to $2.7B; revenue, $2.45B to $2.65B (consensus: $2.47B); gross margin, 46.5% to 48.5%; operating margin, 29% to $31%; EPS, $3.53 to $3.77 (consensus: $3.28).</li>     <li>Shipments were down 6% on the year to $2.38B with the percentage of shipments to China dropping 4% on the year to 10%. Deferred revenues totaled $938M, down from the $966M in the prior year&rsquo;s quarter.</li>     <li>Cash: cash flow from operating activities totaled $858M and went towards $155M in share repurchases, $302M in debt payments, and $73M of dividend payouts. Lam ended the quarter with $6.4B in cash and equivalents.</li>     <li><a href=\"https://seekingalpha.com/pr/16971350-lam-research-corporation-reports-financial-results-quarter-ended-september-24-2017\" target=\"_blank\">Press release</a></li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3301605-lam-research-beats-0_18-beats-revenue\" target=\"_blank\">Lam Research beats by $0.18, beats on revenue</a> (Oct. 17)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301650\" data-linked=\"Lam Research reports Q4, guidance beats but Shipments dropped 6%\" data-tweet=\"$LRCX - Lam Research reports Q4, guidance beats but Shipments dropped 6% https://seekingalpha.com/news/3301650-lam-research-reports-q4-guidance-beats-shipments-dropped-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3301650-lam-research-reports-q4-guidance-beats-shipments-dropped-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301644\" data-ts=\"1508274109\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBM\" target=\"_blank\">IBM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301644-ibm-reports-q3-fy-guidance-beats-sharesplus-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IBM reports Q3, FY guidance beats; shares +4%</a></h4><ul><li>        IBM (NYSE:<a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a>) shares are&nbsp;<font color='green'>up 4.08%</font>&nbsp;aftermarket following Q3 results with revenue and EPS beats. The company forecasts FY17 diluted operating EPS of at least $13.80, compared to $13.75 consensus, with flat FCF on the year.&nbsp;</li><li>        Segment sales: Cognitive Solutions (solutions and transaction processing software), $4.4B (+4% Y/Y, 78.7% profit margin); Global Business Services (consulting, global process services, app management), $4.1B (-2% Y/Y, 27.3% margin); Tech Services &amp; Cloud Platforms (infrastructure services, tech support, integration software), $8.5B (-3% Y/Y, 41.1% margin); Systems (systems hardware, operating systems software), $1.7B (+10% Y/Y, 53.6%); Global Financing, $427M (+4%, 25.2% margin).&nbsp;</li><li>               Other key sales numbers: Cloud revenues were up 20% to $4.1B. Annual exit run rate for as-a-service revenue increased to $9.4B from last year&rsquo;s $7.5B.&nbsp;</li><li>               Financials: Cash from operating activities, excluding Global Financing receivables, totaled $3.3B and FCF was $2.5B. IBM ended the quarter with $11.5B in cash on hand and $45.6B in debt. The company returned $1.4B in dividends, $0.9B in gross share repurchases, and had $1.5B remaining in the current share repurchase authorization as of September.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16971361-ibm-reports-2017-third-quarter-results\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301612-international-business-machines-beats-0_02-beats-revenue\" target=\"_blank\">International Business Machines beats by $0.02, beats on revenue</a> (Oct. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301644\" data-linked=\"IBM reports Q3, FY guidance beats; shares +4%\" data-tweet=\"$IBM - IBM reports Q3, FY guidance beats; shares +4% https://seekingalpha.com/news/3301644-ibm-reports-q3-fy-guidance-beats-sharesplus-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3301644-ibm-reports-q3-fy-guidance-beats-sharesplus-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>57&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301637\" data-ts=\"1508273388\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSKN\" target=\"_blank\">SSKN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301637-strata-skin-sciences-inks-deal-aesthetic-medical-market-focused-group-purchasing-organization\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">STRATA Skin Sciences inks deal with aesthetic medical market-focused group purchasing organization; shares ahead 31% after hours</a></h4><ul><li>Thinly traded nano cap <a href=\"http://www.strataskinsciences.com/\" target=\"_blank\">STRATA Skin Sciences</a> (NASDAQ:<a href='https://seekingalpha.com/symbol/SSKN' title='STRATA Skin Sciences, Inc'>SSKN</a>) is up&nbsp;<font color='green'>31%&nbsp;</font>after hours on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16971313-strata-skin-sciences-announces-agreement-medresults-network-gpo-exclusive-aesthetic-medical\" target=\"_blank\">agreement </a>with MedResults Network &#40;MRN&#41;, a group purchasing organization &#40;GPO&#41; that supports the aesthetic medical market.</li><li>MedResults researches product categories, selects products that deliver substantial value and negotiates pricing for its membership that includes dermatology and plastic surgery practices, facial plastic practices and MediSpas.</li><li>MedResults President Jeff Routledge says, &ldquo;We are excited about the opportunity to assist STRATA in marketing their products to our membership. STRATA&rsquo;s Aesthetic products, Nordlys and STRATAPEN, are excellent products that are in growing sectors of the Aesthetic market. MRN&rsquo;s mission is to offer our members best-in-class products from world class companies through pricing that can only be achieved by leveraging the buying power of our 3,000 member practices and medical spas.&rdquo;</li><li>Full launch to MRN members commences this week.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301637\" data-linked=\"STRATA Skin Sciences inks deal with aesthetic medical market-focused group purchasing organization; shares ahead 31% after hours\" data-tweet=\"$SSKN - STRATA Skin Sciences inks deal with aesthetic medical market-focused group purchasing organization; shares ahead 31% after hours https://seekingalpha.com/news/3301637-strata-skin-sciences-inks-deal-aesthetic-medical-market-focused-group-purchasing-organization?source=tweet\" data-url=\"https://seekingalpha.com/news/3301637-strata-skin-sciences-inks-deal-aesthetic-medical-market-focused-group-purchasing-organization\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301638\" data-ts=\"1508273245\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRI\" target=\"_blank\">TRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301638-thomson-reuters-hits-record-high-after-upgrade-scotiabank\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Thomson Reuters hits record high after upgrade at Scotiabank</a></h4><ul>   <li>Thomson Reuters (<a href=\"http://seekingalpha.com/symbol/TRI\" target=\"_blank\">TRI</a> <font color='green'>+1.7%</font>) reached an all-time high, hitting $48.61, after a boost to Sector Outperform at Scotiabank, which pointed to revenue growth, possible margin expansion and capital returns as positives.</li>    <li>The firm can beat its full-year earnings target of $2.40-$2.45 thanks to organic growth in the financial and risk segment, the firm says. (h/t Bloomberg)</li>    <li>Scotiabank raised its price target to $55 from $47, implying 14.4% upside still ahead.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301638\" data-linked=\"Thomson Reuters hits record high after upgrade at Scotiabank\" data-tweet=\"$TRI - Thomson Reuters hits record high after upgrade at Scotiabank https://seekingalpha.com/news/3301638-thomson-reuters-hits-record-high-after-upgrade-scotiabank?source=tweet\" data-url=\"https://seekingalpha.com/news/3301638-thomson-reuters-hits-record-high-after-upgrade-scotiabank\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301633\" data-ts=\"1508272601\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNMX\" target=\"_blank\">GNMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301633-aevi-genomic-finalizes-28m-private-capital-raise-shares-up-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aevi Genomic finalizes $28M private capital raise; shares up 2% after hours</a></h4><ul><li>Aevi Genomic Medicine (NASDAQ:<a href='https://seekingalpha.com/symbol/GNMX' title='Aevi Genomic Medicine, Inc.'>GNMX</a>) <a href=\"https://seekingalpha.com/pr/16971402-aevi-genomic-medicine-announces-completion-28-million-private-placement\" target=\"_blank\">completes </a>the private placement of 22.2M shares of common stock plus warrants to purchase up to ~4.0M shares of common. The Children's Hospital of Philadelphia Foundation was the lead investor. Gross proceeds were ~$28.0M.</li><li>Net proceeds will fund its two lead clinical programs, its ongoing collaboration with Children's Hospital of Philadelphia and general corporate purposes.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;after hours on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301633\" data-linked=\"Aevi Genomic finalizes $28M private capital raise; shares up 2% after hours\" data-tweet=\"$GNMX - Aevi Genomic finalizes $28M private capital raise; shares up 2% after hours https://seekingalpha.com/news/3301633-aevi-genomic-finalizes-28m-private-capital-raise-shares-up-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3301633-aevi-genomic-finalizes-28m-private-capital-raise-shares-up-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301632\" data-ts=\"1508272583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CREE\" target=\"_blank\">CREE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301632-cree-reports-narrow-q1-guidance-beats-shares-5_3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cree reports narrow Q1, guidance beats; shares - 5.3%</a></h4><ul><li>        Cree (NASDAQ:<a href='https://seekingalpha.com/symbol/CREE' title='Cree, Inc.'>CREE</a>) shares are&nbsp;<font color='red'>down 5.25%</font>&nbsp;aftermarket following Q1 results that met EPS estimates and narrowly beat revenue estimates. The company&rsquo;s Q2 revenue guidance narrowly beats consensus at the high end of the $340M to $360M range and meets EPS with a broad guidance of -$0.01 to $0.04. &nbsp;</li><li>        Segment sales: Lighting products, $149.7M (-19% Y/Y, 21.3% gross margin); LED products, $144.5M (5% Y/Y, 26.9% margin); Wolfspeed, $66M (+33% Y/Y, 49% margin).</li><li>               Expenses: Total operating expenses were down slightly on the year to $114.4M.&nbsp;</li><li>               Key financials: Non-GAAP consolidated gross margin was 27.8%, down from 29.6% in last year&rsquo;s period. Free cash flow was $15.2M compared to a $3.5M loss last year. Cree ended the quarter with $152M in cash and equivalents. SG&amp;A spending had the only notable drop, falling 8% to $63M. R&amp;D accounted for $42M.&nbsp;</li><li>                  <a href=\"https://seekingalpha.com/pr/16971312-cree-reports-financial-results-first-quarter-fiscal-year-2018\" target=\"_blank\">Press release</a>&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3301597-cree-eps-line-beats-revenue\" target=\"_blank\">Cree EPS in-line, beats on revenue</a> (Oct. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301632\" data-linked=\"Cree reports narrow Q1, guidance beats; shares - 5.3%\" data-tweet=\"$CREE - Cree reports narrow Q1, guidance beats; shares - 5.3% https://seekingalpha.com/news/3301632-cree-reports-narrow-q1-guidance-beats-shares-5_3?source=tweet\" data-url=\"https://seekingalpha.com/news/3301632-cree-reports-narrow-q1-guidance-beats-shares-5_3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301631\" data-ts=\"1508272483\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBKR\" target=\"_blank\">IBKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301631-interactive-brokers-up-2_85-after-topping-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interactive Brokers up 2.85% after topping estimates</a></h4><ul><li>Q3 EPS excluding other comprehensive income of $0.43 vs $0.30 one year ago. Expectations were for $0.38.</li><li>Revenue of $426M up from $345M a year ago, with income before taxes of $268M vs. $183M.</li><li>Highlights include net interest income up 34% Y/Y, and commissions up 13%. Trading gains down 71% Y/Y as the wind down of the U.S. options market making business was completed.</li><li><a href=\"http://www.interactivebrokers.com/ir\" target=\"_blank\">Conference call at 4:30 ET</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3301599-interactive-brokers-group-beats-0_05-beats-revenue\" target=\"_blank\">Interactive Brokers Group beats by $0.05, beats on revenue</a> (Oct. 17)</li><li><a href='https://seekingalpha.com/symbol/IBKR' title='Interactive Brokers Group, Inc.'>IBKR</a>&nbsp;<font color='green'>+2.85%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3301631\" data-linked=\"Interactive Brokers up 2.85% after topping estimates\" data-tweet=\"$IBKR - Interactive Brokers up 2.85% after topping estimates https://seekingalpha.com/news/3301631-interactive-brokers-up-2_85-after-topping-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3301631-interactive-brokers-up-2_85-after-topping-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301625\" data-ts=\"1508272023\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAVI\" target=\"_blank\">NAVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301625-navient-beats-0_05-misses-on-net-interest-income\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navient beats by $0.05, misses on net interest income</a></h4><ul><li>Navient (NASDAQ:<a href='https://seekingalpha.com/symbol/NAVI' title='Navient Corp'>NAVI</a>): Q3 EPS of $0.55 <font color='green'>beats by $0.05</font>.</li><li>Net interest income of $343M (-15.3% Y/Y) <font color='red'>misses by $22.4M</font>.</li><li>Shares <font color='green'>+2.4%</font>.</li><li><a href=\"https://seekingalpha.com/filing/3730032\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301625\" data-linked=\"Navient beats by $0.05, misses on net interest income\" data-tweet=\"$NAVI - Navient beats by $0.05, misses on net interest income https://seekingalpha.com/news/3301625-navient-beats-0_05-misses-on-net-interest-income?source=tweet\" data-url=\"https://seekingalpha.com/news/3301625-navient-beats-0_05-misses-on-net-interest-income\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301612\" data-ts=\"1508271156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBM\" target=\"_blank\">IBM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301612-international-business-machines-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">International Business Machines beats by $0.02, beats on revenue</a></h4><ul><li>International Business Machines (NYSE:<a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a>): Q3 EPS of $3.30 <font color='green'>beats by $0.02</font>.</li><li>Revenue of $19.15B (-0.4% Y/Y) <font color='green'>beats by $550M</font>.</li><li>Shares <font color='green'>+1.6%</font>.</li><li><a href='https://seekingalpha.com/pr/16971361-ibm-reports-2017-third-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301612\" data-linked=\"International Business Machines beats by $0.02, beats on revenue\" data-tweet=\"$IBM - International Business Machines beats by $0.02, beats on revenue https://seekingalpha.com/news/3301612-international-business-machines-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3301612-international-business-machines-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301604\" data-ts=\"1508270779\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKTX\" target=\"_blank\">AKTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301604-akari-therapeutics-readies-equity-offering-shares-down-10-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akari Therapeutics readies equity offering; shares down 10% after hours</a></h4><ul><li>Akari Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a>) <a href=\"https://seekingalpha.com/pr/16971317-akari-therapeutics-announces-proposed-public-offering-american-depositary-shares\" target=\"_blank\">initiates </a>a public offering of American Depositary Shares (ADSs). Price, volume and terms have yet to be released.</li><li>Shares are off&nbsp;<font color='red'>10%</font>&nbsp;after hours on modestly higher volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301604\" data-linked=\"Akari Therapeutics readies equity offering; shares down 10% after hours\" data-tweet=\"$AKTX - Akari Therapeutics readies equity offering; shares down 10% after hours https://seekingalpha.com/news/3301604-akari-therapeutics-readies-equity-offering-shares-down-10-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3301604-akari-therapeutics-readies-equity-offering-shares-down-10-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301599\" data-ts=\"1508270563\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBKR\" target=\"_blank\">IBKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301599-interactive-brokers-group-beats-0_05-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interactive Brokers Group beats by $0.05, beats on revenue</a></h4><ul><li>Interactive Brokers Group (IEX:<a href='https://seekingalpha.com/symbol/IBKR' title='Interactive Brokers Group, Inc.'>IBKR</a>): Q3 EPS of $0.43 <font color='green'>beats by $0.05</font>.</li><li>Revenue of $426M (+23.5% Y/Y) <font color='green'>beats by $40.48M</font>.</li><li>Shares <font color='green'>+1.6%</font>.</li><li><a href='https://seekingalpha.com/pr/16971314-interactive-brokers-group-announces-3q2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301599\" data-linked=\"Interactive Brokers Group beats by $0.05, beats on revenue\" data-tweet=\"$IBKR - Interactive Brokers Group beats by $0.05, beats on revenue https://seekingalpha.com/news/3301599-interactive-brokers-group-beats-0_05-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3301599-interactive-brokers-group-beats-0_05-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301595\" data-ts=\"1508270303\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTL\" target=\"_blank\">CTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301595-report-centurylink-still-plans-level-3-close-months-end\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: CenturyLink still plans Level 3 close by month&#39;s end</a></h4><ul>   <li>The day after a 180-day \"shot clock\" expired at the FCC with no comment, CenturyLink (<a href=\"http://seekingalpha.com/symbol/CTL\" target=\"_blank\">CTL</a> <font color='red'>-3.8%</font>) is saying it expects to close on its $34B buyout of Level 3 Communications (<a href=\"http://seekingalpha.com/symbol/LVLT\" target=\"_blank\">LVLT</a> <font color='red'>-2.1%</font>) by month's end, dealReporter says.</li>    <li>That's over the next 14 days. It's a reiteration of the time frame that <a href=\"https://seekingalpha.com/news/3294853-centurylink-updates-level-3-closing-time-frame\" target=\"_blank\">CenturyLink set last month</a>, as it awaited developments in California and at the FCC.</li>    <li>But it had been preparing for an Oct. 16 close after hoping to hear from the FCC.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301595\" data-linked=\"Report: CenturyLink still plans Level 3 close by month&#39;s end\" data-tweet=\"$CTL $CTL $LVLT - Report: CenturyLink still plans Level 3 close by month&#39;s end https://seekingalpha.com/news/3301595-report-centurylink-still-plans-level-3-close-months-end?source=tweet\" data-url=\"https://seekingalpha.com/news/3301595-report-centurylink-still-plans-level-3-close-months-end\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>107&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301594\" data-ts=\"1508270124\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DPS-OLD\" target=\"_blank\">DPS-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301594-soda-sales-weak-per-nielsen-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Soda sales weak per Nielsen data</a></h4><ul><li>A weak read from Nielsen on carbonated soft drink sales is creating some ripples in the beverage sector.</li><li>Nielsen data indicates dollar sales were down 1.5% for the four-week period ending on October 7. Volume was down by over 3% for the period, only partially offset by pricing and mix.</li><li>Soda sector:&nbsp;Dr Pepper Snapper (<a href='https://seekingalpha.com/symbol/DPS-OLD' title='Dr Pepper Snapple Group, Inc.'>DPS-OLD</a> <font color='red'>-0.3%</font>), Coca-Cola (<a href='https://seekingalpha.com/symbol/KO' title='The Coca-Cola Company'>KO</a> <font color='red'>-0.2%</font>), PepsiCo (<a href='https://seekingalpha.com/symbol/PEP' title='PepsiCo Inc.'>PEP</a> <font color='red'>-1.2%</font>), Cott (<a href='https://seekingalpha.com/symbol/COT' title='Cott Corporation'>COT</a> <font color='red'>-0.6%</font>), National Beverage (<a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a> <font color='red'>-8.3%</font>), Reed's (<a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a> <font color='red'>-3.7%</font>), Jones Soda (<a href='https://seekingalpha.com/symbol/JSDA' title='Jones Soda Co.'>OTC:JSDA</a> <font color='red'>-1.1%</font>), New Age Beverages (<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='red'>-1.6%</font>), Monster Beverage (<a href='https://seekingalpha.com/symbol/MNST' title='Monster Beverage Corp.'>MNST</a> <font color='green'>+0.6%</font>).</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3301594\" data-linked=\"Soda sales weak per Nielsen data\" data-tweet=\"$DPS-OLD $DPS-OLD $KO - Soda sales weak per Nielsen data https://seekingalpha.com/news/3301594-soda-sales-weak-per-nielsen-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3301594-soda-sales-weak-per-nielsen-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301589\" data-ts=\"1508268949\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TYL\" target=\"_blank\">TYL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301589-keybanc-downgrades-tyler-technologies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KeyBanc downgrades Tyler Technologies</a></h4><ul><li>        KeyBanc downgrades Tyler Technologies (NYSE:<a href='https://seekingalpha.com/symbol/TYL' title='Tyler Technologies, Inc.'>TYL</a>) from Overweight to Sector Weight.</li><li>                  Analyst Brent Bracelin cites valuation as shares approach his $180 price target.    </li><li>               Source: <a href=\"https://thefly.com/landingPageNews.php?id=2623651&amp;headline=TYL-Tyler-Technologies-downgraded-to-Sector-Weight-from-Overweight-at-KeyBanc\" target=\"_blank\">The Fly</a>&nbsp;</li><li>                  Tyler Technologies shares are down 2.25%. &nbsp;&nbsp;&nbsp;&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3301589\" data-linked=\"KeyBanc downgrades Tyler Technologies\" data-tweet=\"$TYL - KeyBanc downgrades Tyler Technologies https://seekingalpha.com/news/3301589-keybanc-downgrades-tyler-technologies?source=tweet\" data-url=\"https://seekingalpha.com/news/3301589-keybanc-downgrades-tyler-technologies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301588\" data-ts=\"1508268476\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOX\" target=\"_blank\">FOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301588-fox-iheartmedia-team-on-new-music-competition-show\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fox, iHeartMedia team on new music competition show</a></h4><ul>   <li>Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='green'>+0.2%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='green'>+0.4%</font>) is turning to <a href=\"http://www.adweek.com/tv-video/fox-taps-iheartmedia-to-help-launch-its-post-american-idol-music-competition-series/\" target=\"_blank\">partner with iHeartMedia</a> (<a href=\"http://seekingalpha.com/symbol/IHRT\" target=\"_blank\">IHRT</a> <font color='red'>-9.3%</font>) as it works to develop its first music competition since letting go of megahit <i>American Idol.</i></li>    <li>The radio giant will help Fox on <i>The Four: Battle for Stardom,</i> by leveraging its radio and streaming networks for the music from the show's competitors as well as assisting with auditions and talent search.</li>    <li>That will come with the development of Smart A/V Audiences, data-based advertising offerings with integrated audio and video creative units.</li>    <li><i>The Four</i> will start with four finalists chosen from auditions who need to defend their spots from new challenger singers each week.</li>    <li>For its part, iHeart brings to the table more than 250M monthly listeners in the U.S. and a digital platform (iHeartRadio) with more than 100M registered users.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301588\" data-linked=\"Fox, iHeartMedia team on new music competition show\" data-tweet=\"$FOX $FOX $FOXA - Fox, iHeartMedia team on new music competition show https://seekingalpha.com/news/3301588-fox-iheartmedia-team-on-new-music-competition-show?source=tweet\" data-url=\"https://seekingalpha.com/news/3301588-fox-iheartmedia-team-on-new-music-competition-show\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301585\" data-ts=\"1508268152\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OSUR\" target=\"_blank\">OSUR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301585-selloff-in-orasure-gathers-pace-shares-down-8-on-heavy-volume\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Selloff in Orasure gathers pace, shares down 8% on heavy volume</a></h4><ul><li>Buyers are scarce in point-of-care testing outfit Orasure (<a href='https://seekingalpha.com/symbol/OSUR' title='OraSure Technologies, Inc.'>OSUR</a> <font color='red'>-8.2%</font>). Shares are down on almost five times normal volume and have given up almost 16% of their value this month.</li><li>No particular news accounts for the bearish action, although some profit taking should be expected considering the stock's consistent 2.5x up move this year.</li><li>The company is scheduled to release <a href=\"https://seekingalpha.com/pr/16965063-orasure-technologies-earnings-conference-call-invitation\" target=\"_blank\">Q3 results</a> after the close on Wednesday, November 1. Consensus view is EPS of $0.09 (-18.2%) on revenues of $40.8M (+26.3%).</li></ul><div class=\"tiny-share-widget\" data-id=\"3301585\" data-linked=\"Selloff in Orasure gathers pace, shares down 8% on heavy volume\" data-tweet=\"$OSUR - Selloff in Orasure gathers pace, shares down 8% on heavy volume https://seekingalpha.com/news/3301585-selloff-in-orasure-gathers-pace-shares-down-8-on-heavy-volume?source=tweet\" data-url=\"https://seekingalpha.com/news/3301585-selloff-in-orasure-gathers-pace-shares-down-8-on-heavy-volume\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301580\" data-ts=\"1508266669\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301580-freeport-mcmoran-dynegy-cut-to-sell-deutsche-bank\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Freeport McMoran, Dynegy both cut to Sell at Deutsche Bank</a></h4><ul>     <li>Deutsche Bank is out today with two downgrades to Sell: Freeport McMoRan (<a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a> <font color='red'>-2.3%</font>) is <a href=\"http://thefly.com/thestreet/realmoney/index.php/FCXid2623638/FCX-Freeport-McMoRan-downgraded-to-Sell-from-Hold-at-Deutsche-Bank\" target=\"_blank\">cut to Sell</a> from Hold with an unchanged $13 price target, as the firm sees an unfavorable risk/reward profile due to valuation and continued uncertainty at the Grasberg mine in Indonesia.</li>     <li>Deutsche Bank also <a href=\"http://thefly.com/thestreet/realmoney/index.php/DYNid2624045/DYN-Dynegy-downgraded-to-Sell-from-Hold-at-Deutsche-Bank\" target=\"_blank\">downgrades</a> Dynegy (<a href='https://seekingalpha.com/symbol/DYN' title='Dynegy Inc.'>DYN</a> <font color='red'>-3.3%</font>) to Sell with a price target cut to $7 from $10, as the firm believes the stock's recent rally  prices in expectations for an acquisition and leaves little room for disappointment.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301580\" data-linked=\"Freeport McMoran, Dynegy both cut to Sell at Deutsche Bank\" data-tweet=\"$FCX $FCX $DYN - Freeport McMoran, Dynegy both cut to Sell at Deutsche Bank https://seekingalpha.com/news/3301580-freeport-mcmoran-dynegy-cut-to-sell-deutsche-bank?source=tweet\" data-url=\"https://seekingalpha.com/news/3301580-freeport-mcmoran-dynegy-cut-to-sell-deutsche-bank\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301578\" data-ts=\"1508266521\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301578-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SYNT' title='Syntel, Inc.'>SYNT</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/GRVY' title='GRAVITY Co., Ltd. - American depositary shares, each representing one'>GRVY</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/TRHC' title='Tabula Rasa HealthCare'>TRHC</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/LEDS' title='SemiLEDs Corporation'>LEDS</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/INSG' title='Inseego Corp.'>INSG</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/BMI' title='Badger Meter, Inc.'>BMI</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/APDN' title='Applied DNA Sciences, Inc.'>APDN</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301578\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$SYNT $GRVY $TRHC - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3301578-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3301578-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301576\" data-ts=\"1508266038\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYH\" target=\"_blank\">CYH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301576-healthcare-sector-on-move-after-senate-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare sector on the move after Senate deal</a></h4><ul><li>The S&amp;P 500 is flat, but the Health Care SPDR (<a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a> <font color='green'>+1.4%</font>) is having a big session after Republican Senator Alexander <a href=\"http://www.politico.com/story/2017/10/17/alexander-and-murray-say-theyve-struck-bipartisan-obamacare-deal-243872\" target=\"_blank\">says he and</a> Democrat counterpart Patty Murray have come to terms on a deal for legislation to resume bailout payments to insurers. The president, last week, had signed an executive order blocking the payments.</li><li>Hospitals: Community Health (<a href='https://seekingalpha.com/symbol/CYH' title='Community Health Systems, Inc.'>CYH</a> <font color='green'>+5.4%</font>), Universal Health (<a href='https://seekingalpha.com/symbol/UHS' title='Universal Health Services Inc.'>UHS</a> <font color='green'>+2.3%</font>), HCA Health (<a href='https://seekingalpha.com/symbol/HCA' title='HCA Holdings, Inc.'>HCA</a> <font color='green'>+2.3%</font>), Tenet Health (<a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a> <font color='green'>+3.8%</font>)</li><li>Insurers: UnitedHealth (<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a> <font color='green'>+6.1%</font>), Aetna (<a href='https://seekingalpha.com/symbol/AET' title='Aetna, Inc.'>AET</a> <font color='green'>+2.6%</font>), Cigna (<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a> <font color='green'>+1.4%</font>), Anthem (<a href='https://seekingalpha.com/symbol/ANTM' title='Anthem, Inc.'>ANTM</a> <font color='green'>+2.6%</font>), Humana (<a href='https://seekingalpha.com/symbol/HUM' title='Humana Inc.'>HUM</a> <font color='green'>+1.7%</font>), Molina (<a href='https://seekingalpha.com/symbol/MOH' title='Molina Healthcare, Inc.'>MOH</a> <font color='green'>+3.2%</font>), Centene (<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a> <font color='green'>+2.8%</font>), WellCare (<a href='https://seekingalpha.com/symbol/WCG' title='WellCare Health Plans, Inc.'>WCG</a> <font color='green'>+3.3%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a>, <a href='https://seekingalpha.com/symbol/VHT' title='Vanguard Health Care ETF'>VHT</a>, <a href='https://seekingalpha.com/symbol/IYH' title='iShares U.S. Healthcare ETF'>IYH</a>, <a href='https://seekingalpha.com/symbol/HQH' title='Tekla Healthcare Investors'>HQH</a>, <a href='https://seekingalpha.com/symbol/CURE' title='Direxion Daily Healthcare Bull 3x Shares ETF'>CURE</a>, <a href='https://seekingalpha.com/symbol/THQ' title='Tekla Healthcare Opportunities Fund'>THQ</a>, <a href='https://seekingalpha.com/symbol/FHLC' title='Fidelity MSCI Health Care Index ETF'>FHLC</a>, <a href='https://seekingalpha.com/symbol/FXH' title='First Trust Health Care AlphaDEX ETF'>FXH</a>, <a href='https://seekingalpha.com/symbol/RXL' title='ProShares Ultra Health Care ETF'>RXL</a>, <a href='https://seekingalpha.com/symbol/RYH' title='Invesco S&P Equal Weight Health Care ETF'>RYH</a>, <a href='https://seekingalpha.com/symbol/RXD' title='ProShares UltraShort Health Care ETF'>RXD</a>, <a href='https://seekingalpha.com/symbol/SICK' title='Daily Healthcare Bear 3x Shares ETF'>SICK</a>, <a href='https://seekingalpha.com/symbol/LNGR' title='Global X Longevity Thematic ETF'>LNGR</a>, <a href='https://seekingalpha.com/symbol/BTEC' title='Principal Healthcare Innovators Index ETF'>BTEC</a>, <a href='https://seekingalpha.com/symbol/JHMH' title='John Hancock Multifactor Healthcare ETF'>JHMH</a>, <a href='https://seekingalpha.com/symbol/HCRF' title='iShares Edge MSCI Multifactor Healthcare ETF'>HCRF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301576\" data-linked=\"Healthcare sector on the move after Senate deal\" data-tweet=\"$CYH $XLV $CYH - Healthcare sector on the move after Senate deal https://seekingalpha.com/news/3301576-healthcare-sector-on-move-after-senate-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3301576-healthcare-sector-on-move-after-senate-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>98&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301574\" data-ts=\"1508265819\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301574-california-wildfire-attorney-says-pg-and-e-be-liable-for-up-to-6b-damages\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">California wildfire attorney says PG&amp;E could be liable for up to $6B damages</a></h4><ul>     <li>Pacific Gas &amp;&nbsp;Electric (<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color='green'>+8.1%</font>) recoups a chunk of its <a href=\"https://seekingalpha.com/news/3301215-pg-and-e-extends-plunge-21-month-lows-worry-california-fire-liability\" target=\"_blank\">steep losses from recent days</a>, perhaps as investors ascertain that Cal Fire and the California Public Utilities Commission have cited <a href=\"http://www.sacbee.com/news/local/article179217751.html\" target=\"_blank\">no evidence</a> that the company contributed to any the deadly northern California wildfires; shares are still down 18% since last Thursday.</li>     <li>But the speculation goes on, with an attorney specializing in wildfire lawsuits saying PG&amp;E potentially could be <a href=\"https://www.cnbc.com/2017/10/17/attorney-who-sued-pge-faults-california-for-history-of-utility-disasters.html\" target=\"_blank\">on the hook for $5B-$6B in damages</a> if found liable for the wildfires.</li>     <li>\"From everything we've learned, it looks like PG&amp;E is responsible for at least some of the fires,\" and likely to \"dwarf all the other ones\" that involved fires linked to California utilities, Gerald Singleton tells CNBC.</li>     <li>Singleton claims there is a history of California's investor-owned energy utilities generally failing to perform proper maintenance.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301574\" data-linked=\"California wildfire attorney says PG&amp;E could be liable for up to $6B damages\" data-tweet=\"$PCG - California wildfire attorney says PG&amp;E could be liable for up to $6B damages https://seekingalpha.com/news/3301574-california-wildfire-attorney-says-pg-and-e-be-liable-for-up-to-6b-damages?source=tweet\" data-url=\"https://seekingalpha.com/news/3301574-california-wildfire-attorney-says-pg-and-e-be-liable-for-up-to-6b-damages\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301569\" data-ts=\"1508263244\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301569-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CLD' title='Cloud Peak Energy, Inc.'>CLD</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CHNR' title='China Natural Resources, Inc.'>CHNR</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/KMG' title='KMG Chemicals, Inc.'>KMG</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/JONE' title='Jones Energy, Inc.'>OTC:JONE</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301569\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$CLDPQ $CHNR $ERN - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3301569-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3301569-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301562\" data-ts=\"1508260575\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMDZ\" target=\"_blank\">IMDZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301562-wells-downgrade-weighs-on-immune-design-shares-down-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells downgrade weighs on Immune Design; shares down 13%</a></h4><ul><li>Thinly traded micro cap Immune Design (<a href='https://seekingalpha.com/symbol/IMDZ' title='Immune Design'>IMDZ</a> <font color='red'>-12.9%</font>) slumps on more than 4x higher volume on the heels of a downgrade to Market Perform by Wells Fargo.</li><li>RBC is staying the course, raising its price target to $23 (160% upside) from $20 while maintaining its Outperform rating.</li><li>Yesterday after the close, the company announced that it will launch a Phase 3 study in mid-2018 evaluating prime-boost vaccine candidate CMB305 in patients with metastatic/inoperable NY-ESO-1-positive synovial sarcoma.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301329-immune-design-launch-pivotal-study-cancer-vaccine-candidate-cmb305-shares-ahead-9-percent\" target=\"_blank\">Immune Design to launch pivotal study for cancer vaccine candidate CMB305; shares ahead 9% after hours</a> (Oct. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301562\" data-linked=\"Wells downgrade weighs on Immune Design; shares down 13%\" data-tweet=\"$IMDZ - Wells downgrade weighs on Immune Design; shares down 13% https://seekingalpha.com/news/3301562-wells-downgrade-weighs-on-immune-design-shares-down-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3301562-wells-downgrade-weighs-on-immune-design-shares-down-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301560\" data-ts=\"1508259874\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOS\" target=\"_blank\">MOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301560-mosaic-moves-lower-rbc-cites-uncertainty-on-outlook-irma-damage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mosaic moves lower as RBC cites uncertainty on outlook, Irma damage</a></h4><ul>     <li>Mosaic (<a href='https://seekingalpha.com/symbol/MOS' title='The Mosaic Company'>MOS</a> <font color='red'>-3.7%</font>) sinks more than 3% after RBC Capital says it sees <a href=\"https://timesofindia.indiatimes.com/business/international-business/mosaic-co-ops-uncertainty-and-vale-buy-to-weigh-rbc/articleshow/61121456.cms\" target=\"_blank\">significant uncertainty</a> in the company's financial performance due  to operational issues and the pending $2.5B deal for Vale's (<a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color='red'>-2%</font>)  fertilizer unit, which the firm says was at a relatively high price.</li>     <li>RBC, which maintains its Sector Perform rating and trims its stock price target to $22 from $23, also estimates a $0.05/share hit on the company's Q3 earnings from Hurricane Irma.</li><li>North American fertilizer producers Potash Corp. (POT <font color='red'>-1.5%</font>) and Agrium (AGU <font color='red'>-1.7%</font>) also are lower.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301560\" data-linked=\"Mosaic moves lower as RBC cites uncertainty on outlook, Irma damage\" data-tweet=\"$MOS $MOS $VALE - Mosaic moves lower as RBC cites uncertainty on outlook, Irma damage https://seekingalpha.com/news/3301560-mosaic-moves-lower-rbc-cites-uncertainty-on-outlook-irma-damage?source=tweet\" data-url=\"https://seekingalpha.com/news/3301560-mosaic-moves-lower-rbc-cites-uncertainty-on-outlook-irma-damage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301559\" data-ts=\"1508259848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301559-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CCCR-OLD' title='China Commercial Credit'>CCCR-OLD</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TCAP-OLD' title='Triangle Capital'>TCAP-OLD</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SGLB' title='Sigma Labs, Inc.'>SGLB</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings'>JP</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/FRSX' title='Foresight Autonomous Holdings Ltd.'>FRSX</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301559\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$CCCR-OLD $PN $TCAP-OLD - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3301559-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3301559-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301554\" data-ts=\"1508258828\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SONC\" target=\"_blank\">SONC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301554-post-earnings-rally-for-sonic\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Post-earnings rally for Sonic</a></h4><ul>     <li>Sonic (<a href='https://seekingalpha.com/symbol/SONC' title='Sonic Corp.'>SONC</a> <font color='green'>+5.6%</font>) rallies after topping Q3 estimates. An elevated level of short interest on Sonic may be adding to volatility.</li><li>The results weren't strong enough to push Canaccord Genuity off its Hold ratings.</li>     <li>\"While we are encouraged that the company's new value messaging ($2.99 carhop classic) is resonating and underlying SSS have improved thus far in Q1, we look for greater evidence of sustainability before becoming more constructive on shares,\" writes analyst Lynne Collier.</li><li>Guggenheim keeps a Buy rating on the restaurant stock and slide its price target to $29.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301293-sonic-beats-0_02-misses-revenue\" target=\"_blank\">Sonic beats by $0.02, misses on revenue</a> (Oct. 16)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301303-sonic-lower-revenue-shortfall\" target=\"_blank\">Sonic lower after revenue shortfall</a> (Oct. 16)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301554\" data-linked=\"Post-earnings rally for Sonic\" data-tweet=\"$SONC - Post-earnings rally for Sonic https://seekingalpha.com/news/3301554-post-earnings-rally-for-sonic?source=tweet\" data-url=\"https://seekingalpha.com/news/3301554-post-earnings-rally-for-sonic\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301553\" data-ts=\"1508258713\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301553-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a> <font color='green'>+49%</font>. <a href='https://seekingalpha.com/symbol/GRVY' title='GRAVITY Co., Ltd. - American depositary shares, each representing one'>GRVY</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/DEST' title='Destination Maternity Corporation'>DEST</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/SYNT' title='Syntel, Inc.'>SYNT</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/TERP' title='TerraForm Power, Inc.'>TERP</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CLD' title='Cloud Peak Energy, Inc.'>CLD</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/CCCR-OLD' title='China Commercial Credit'>CCCR-OLD</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/BNTC' title='Benitec'>BNTC</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/VYGR' title='Voyager Therapeutics'>VYGR</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/IMDZ' title='Immune Design'>IMDZ</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/BMI' title='Badger Meter, Inc.'>BMI</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/LBIX-OLD' title='Leading Brands Inc'>LBIX-OLD</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/VICL' title='Vical Incorporated'>VICL</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/APDN' title='Applied DNA Sciences, Inc.'>APDN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a> <font color='red'>-12%</font>. MLNK <font color='red'>-12%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301553\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$TRXC $GRVY $DFFN - Midday Gainers / Losers https://seekingalpha.com/news/3301553-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3301553-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301551\" data-ts=\"1508258195\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CE\" target=\"_blank\">CE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301551-eu-to-investigate-proposed-celanese-blackstone-joint-venture\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EU to investigate proposed Celanese-Blackstone joint venture</a></h4><ul>     <li>Celanese (<a href='https://seekingalpha.com/symbol/CE' title='Celanese Corporation'>CE</a> <font color='red'>-4.2%</font>) shares slide following headlines that the <a href=\"http://europa.eu/rapid/press-release_IP-17-3984_en.htm\" target=\"_blank\">European Union will investigate</a> the company's proposed joint venture with Blackstone (<a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group L.P.'>BX</a> <font color='red'>-0.5%</font>).</li>     <li>The European Commission says the deal <a href=\"https://uk.reuters.com/article/uk-celanese-us-de-m-a-blackstone-group-e/eu-regulators-to-investigate-blackstone-celanese-acetate-tow-merger-idUKKBN1CM2AH\" target=\"_blank\">may reduce competition</a> in the acetate tow market, and that a greater likelihood of tacit coordination between tow suppliers would result from the deal.</li><li>The EU antitrust enforcer will decide by March 5 whether to clear or block the deal.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301551\" data-linked=\"EU to investigate proposed Celanese-Blackstone joint venture\" data-tweet=\"$CE $CE $BX - EU to investigate proposed Celanese-Blackstone joint venture https://seekingalpha.com/news/3301551-eu-to-investigate-proposed-celanese-blackstone-joint-venture?source=tweet\" data-url=\"https://seekingalpha.com/news/3301551-eu-to-investigate-proposed-celanese-blackstone-joint-venture\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301550\" data-ts=\"1508258153\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OSTK\" target=\"_blank\">OSTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301550-blockchain-potential-sends-overstock-com-to-52-week-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blockchain potential sends Overstock.com to 52-week high</a></h4><ul>     <li>Overstock.com (NASDAQ:<a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>) is&nbsp;<font color='green'>up 9%</font>&nbsp;to carve out a new 52-week high of $33.45.</li>     <li>Shares of Overstock are now up 18% since last week when notable short seller Marc Cohodes <a href=\"https://www.bloomberg.com/news/articles/2017-10-10/short-seller-cohodes-unveils-overstock-long-in-u-turn-on-old-foe\" target=\"_blank\">called</a> the e-commerce stock undervalued due to the potential of the blockchain unit.</li>     <li>The tZERO unit aims to use blockchain technology in financial markets.</li>     <li>\"If this thing takes off, the company is going to sell at a whole lot more than a $700 million market cap. The stock will go apoplectic,\" gushed Cohodes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301550\" data-linked=\"Blockchain potential sends Overstock.com to 52-week high\" data-tweet=\"$OSTK - Blockchain potential sends Overstock.com to 52-week high https://seekingalpha.com/news/3301550-blockchain-potential-sends-overstock-com-to-52-week-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3301550-blockchain-potential-sends-overstock-com-to-52-week-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301547\" data-ts=\"1508257584\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMT\" target=\"_blank\">AMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301547-softbank-lendlease-plan-jv-to-buy-8000-u-s-cell-towers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SoftBank, Lendlease plan JV to buy 8,000 U.S. cell towers</a></h4><ul>   <li>SoftBank (<a href=\"http://seekingalpha.com/symbol/SFTBY\" target=\"_blank\">SFTBY</a> <font color='red'>-1.5%</font>) is pairing with Australia's Lendlease Group (<a href=\"http://seekingalpha.com/symbol/LLESY\" target=\"_blank\">LLESY</a> <font color='green'>+2%</font>) in a joint venture planning to take on entrenched U.S. cell tower operators by <a href=\"https://www.wsj.com/articles/softbank-creates-venture-to-buy-8-000-cellular-sites-across-u-s-1508256334\" target=\"_blank\">buying about 8,000 American sites</a>.</li>    <li>A lot of that planned inventory will come from SoftBank's Sprint (<a href=\"http://seekingalpha.com/symbol/S\" target=\"_blank\">S</a> <font color='red'>-0.9%</font>), which will sell rooftop transmitters among other sites.</li>    <li>SoftBank and Lendlease will each initially contribute $200M but plan to buy $5B in telecom assets in the medium term, they said.</li>    <li>Among competing tower operators: American Tower (NYSE:<a href='https://seekingalpha.com/symbol/AMT' title='American Tower Corporation'>AMT</a>) <font color='red'>down 0.7%</font>; Crown Castle (NYSE:<a href='https://seekingalpha.com/symbol/CCI' title='Crown Castle International Corp.'>CCI</a>) <font color='red'>down 0.4%</font>; SBA Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/SBAC' title='SBA Communications Corporation'>SBAC</a>) <font color='red'>down 0.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301547\" data-linked=\"SoftBank, Lendlease plan JV to buy 8,000 U.S. cell towers\" data-tweet=\"$AMT $AMT $CCI - SoftBank, Lendlease plan JV to buy 8,000 U.S. cell towers https://seekingalpha.com/news/3301547-softbank-lendlease-plan-jv-to-buy-8000-u-s-cell-towers?source=tweet\" data-url=\"https://seekingalpha.com/news/3301547-softbank-lendlease-plan-jv-to-buy-8000-u-s-cell-towers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301544\" data-ts=\"1508256866\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DESP\" target=\"_blank\">DESP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301544-despegar-com-falls-back-after-coolish-citi-initiation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Despegar.com falls back after coolish Citi initiation</a></h4><ul><li>Shares of Despegar.com (NYSE:<a href='https://seekingalpha.com/symbol/DESP' title='Despegar.com'>DESP</a>) are&nbsp;<font color='red'>down 2.56%</font>&nbsp;after Citi analyst Mark May warns further upside is limited. May and team rate the Latin American online travel stock at Neutral.</li><li>Despegar peaked on October 12 at $34.70 compared to the $26 mark where the IPO was priced.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301110-analyst-coverage-launches-despegar-com\" target=\"_blank\">Analyst coverage launches on Despegar.com</a> (Oct. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301544\" data-linked=\"Despegar.com falls back after coolish Citi initiation\" data-tweet=\"$DESP - Despegar.com falls back after coolish Citi initiation https://seekingalpha.com/news/3301544-despegar-com-falls-back-after-coolish-citi-initiation?source=tweet\" data-url=\"https://seekingalpha.com/news/3301544-despegar-com-falls-back-after-coolish-citi-initiation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301543\" data-ts=\"1508256519\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNDX\" target=\"_blank\">SNDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301543-syndax-in-licenses-blood-cancer-candidates-from-vitae-pharma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Syndax in-licenses blood cancer candidates from Vitae Pharma</a></h4><ul><li>Syndax Pharmaceuticals (<a href='https://seekingalpha.com/symbol/SNDX' title='Syndax Pharmaceuticals, Inc.'>SNDX</a> <font color='red'>-2.7%</font>) inks an <a href=\"https://seekingalpha.com/pr/16970109-syndax-expands-pipeline-exclusive-worldwide-license-allergans-portfolio-menin-mll-inhibitors\" target=\"_blank\">agreement </a>with Allergan (<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color='green'>+0.8%</font>) unit Vitae Pharmaceuticals for exclusive global rights to a portfolio of preclinical-stage small molecule leukemia candidates.</li><li>The compounds inhibit the interaction of a protein called Menin with the Mixed Lineage Leukemia &#40;MLL&#41; protein, a potential target for the treatment of a subset of acute leukemias characterized by mutations in the MLL gene.</li><li>Clinical studies should commence in 2019.</li><li>Under the terms of the agreement, Syndax will pay an unspecified amount upfront, milestones and tiered royalties on net sales of commercialized products. Specific financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301543\" data-linked=\"Syndax in-licenses blood cancer candidates from Vitae Pharma\" data-tweet=\"$SNDX $SNDX $AGN - Syndax in-licenses blood cancer candidates from Vitae Pharma https://seekingalpha.com/news/3301543-syndax-in-licenses-blood-cancer-candidates-from-vitae-pharma?source=tweet\" data-url=\"https://seekingalpha.com/news/3301543-syndax-in-licenses-blood-cancer-candidates-from-vitae-pharma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301540\" data-ts=\"1508256066\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301540-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a> <font color='green'>+8%</font></li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/LBIX-OLD' title='Leading Brands Inc'>LBIX-OLD</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CAW' title='CCA Industries Inc'>CAW</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a> <font color='red'>-5%</font>. XNY <font color='red'>-5%</font>. [[]] <font color='red'>%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301540\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$SORL $LBIX-OLD $CAW - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3301540-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3301540-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301539\" data-ts=\"1508256050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WHLR\" target=\"_blank\">WHLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301539-day-two-of-losses-for-wheeler-real-estate-shares-off-another-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Day two of losses for Wheeler Real Estate; shares off another 7%</a></h4><ul><li>Seeking Alpha contributor Beyond Saving <a href=\"https://seekingalpha.com/article/4113713-wheeler-kicking-can\" target=\"_blank\">yesterday reiterated a call </a>to avoid Wheeler (<a href='https://seekingalpha.com/symbol/WHLR' title='Wheeler Real Estate Investment Trust'>WHLR</a> <font color='red'>-7.1%</font>). The market mostly ignored a 4th amendment to Wheeler's KeyBanc credit agreement extending by two months the deadline for reducing the amount outstanding to $50M (it was $68M at the end of Q2).</li><li>If Wheeler is having trouble paying off $18M, what happens when the $50M matures next May?</li><li>KeyBanc will no doubt work to extend the maturity, but there will certainly be a cost to Wheeler.</li><li>The author also notes three anchor spaces totaling more than 140K square feet going vacant in Q3.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301539\" data-linked=\"Day two of losses for Wheeler Real Estate; shares off another 7%\" data-tweet=\"$WHLR - Day two of losses for Wheeler Real Estate; shares off another 7% https://seekingalpha.com/news/3301539-day-two-of-losses-for-wheeler-real-estate-shares-off-another-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3301539-day-two-of-losses-for-wheeler-real-estate-shares-off-another-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301535\" data-ts=\"1508255535\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCAP-OLD\" target=\"_blank\">TCAP-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301535-triangle-capital-down-nearly-10-on-downgrade-to-underperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Triangle Capital down nearly 10% on downgrade to Underperform</a></h4><ul><li>Details aren't available, but Raymond James' Robert Dodd overnight downgraded Triangle Capital (<a href='https://seekingalpha.com/symbol/TCAP-OLD' title='Triangle Capital'>TCAP-OLD</a> <font color='red'>-9.6%</font>) to Underperform from Market Perform.</li><li>Shares are now&nbsp;<font color='red'>down nearly 35%</font>&nbsp;YTD.</li><li>Q3 earnings are set to be released on November 2.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301535\" data-linked=\"Triangle Capital down nearly 10% on downgrade to Underperform\" data-tweet=\"$TCAP-OLD - Triangle Capital down nearly 10% on downgrade to Underperform https://seekingalpha.com/news/3301535-triangle-capital-down-nearly-10-on-downgrade-to-underperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3301535-triangle-capital-down-nearly-10-on-downgrade-to-underperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301533\" data-ts=\"1508254828\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEAR\" target=\"_blank\">TEAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301533-tearlab-tweaks-regulatory-strategy-for-inflammatory-biomarkers-mmpminus-9-to-be-prioritized\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TearLab tweaks regulatory strategy for inflammatory biomarkers, MMP-9 to be prioritized; shares slip 4%</a></h4><ul><li>TearLabs (<a href='https://seekingalpha.com/symbol/TEAR' title='TearLab Corporation'>TEAR</a> <font color='red'>-4.4%</font>) has <a href=\"https://seekingalpha.com/pr/16970187-tearlab-corporation-provides-update-u-s-regulatory-strategy-tearlab-discovery-system\" target=\"_blank\">adjusted its regulatory strategy</a> related to tests for its in vitro diagnostics testing platform. It will now pursue FDA clearance for a single inflammatory biomarker, MMP-9, in combination with its osmolarity test. Previously, it planned to seek approval for a test card containing two inflammatory biomarkers plus osmolarity.</li><li>The biomarker + osmolarity is designed to aid in the diagnosis and management of dry eye disease.</li><li>The company says the change in strategy will not impact its guidance related to the timing of the 510(k) application for the TearLab Discovery System, expected by year-end.</li><li>Shares have sold off over 30% since touching $1.94 on October 6.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301533\" data-linked=\"TearLab tweaks regulatory strategy for inflammatory biomarkers, MMP-9 to be prioritized; shares slip 4%\" data-tweet=\"$TEAR - TearLab tweaks regulatory strategy for inflammatory biomarkers, MMP-9 to be prioritized; shares slip 4% https://seekingalpha.com/news/3301533-tearlab-tweaks-regulatory-strategy-for-inflammatory-biomarkers-mmpminus-9-to-be-prioritized?source=tweet\" data-url=\"https://seekingalpha.com/news/3301533-tearlab-tweaks-regulatory-strategy-for-inflammatory-biomarkers-mmpminus-9-to-be-prioritized\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301532\" data-ts=\"1508254105\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TERP\" target=\"_blank\">TERP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301532-terraform-powerplus-38-brookfield-officially-becomes-sponsor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TerraForm Power +38% as Brookfield officially becomes sponsor</a></h4><ul>     <li>TerraForm Power (<a href='https://seekingalpha.com/symbol/TERP' title='TerraForm Power, Inc.'>TERP</a> <font color='green'>+38.1%</font>) skyrockets after Brookfield Asset Management (<a href='https://seekingalpha.com/symbol/BAM' title='Brookfield Asset Management Inc.'>BAM</a> <font color='green'>+0.5%</font>) formally <a href=\"https://globenewswire.com/news-release/2017/10/16/1148396/0/en/TerraForm-Power-Closes-Merger-and-Sponsorship-Transaction.html\" target=\"_blank\">completes its acquisition</a> of a 51% stake in the renewables yieldco, BAM also is now TERP's new sponsor, replacing SunEdison, which went bankrupt earlier this year.</li>     <li>In <a href=\"https://www.sec.gov/Archives/edgar/data/1599947/000156761917002200/0001567619-17-002200-index.htm\" target=\"_blank\">presentation slides</a>, TERP says it expects FY&nbsp;2017 pro-forma FY net losses of $185M-$205M2017 revenue of $575M-$595M, cash available for distribution of $105M-$125M, and adjusted EBITDA of $430M-$450M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301532\" data-linked=\"TerraForm Power +38% as Brookfield officially becomes sponsor\" data-tweet=\"$TERP $TERP $BAM - TerraForm Power +38% as Brookfield officially becomes sponsor https://seekingalpha.com/news/3301532-terraform-powerplus-38-brookfield-officially-becomes-sponsor?source=tweet\" data-url=\"https://seekingalpha.com/news/3301532-terraform-powerplus-38-brookfield-officially-becomes-sponsor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301526\" data-ts=\"1508253251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SARTF\" target=\"_blank\">SARTF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301526-softer-outlook-from-sartorius-pressures-lab-products-makers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Softer outlook from Sartorius pressures lab products makers</a></h4><ul><li>Lower sales and margin forecasts from lab products maker <a href=\"https://www.sartorius.com/sartorius/en/EUR/home//\" target=\"_blank\">Sartorius AG</a>&nbsp;(<a href='https://seekingalpha.com/symbol/SARTF' title='Sartorius AG'>OTC:SARTF</a>) is weighing on others in the space. The G&ouml;ttingen, Germany-based firm cut its outlook after weaker-than-expected results at its Bioprocess Solutions unit.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/PKI' title='PerkinElmer, Inc.'>PKI</a> <font color='red'>-1.6%</font>)(<a href='https://seekingalpha.com/symbol/TMO' title='Thermo Fisher Scientific Inc.'>TMO</a> <font color='red'>-1.6%</font>)(<a href='https://seekingalpha.com/symbol/WAT' title='Waters Corporation'>WAT</a> <font color='red'>-1.5%</font>)</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3301526\" data-linked=\"Softer outlook from Sartorius pressures lab products makers\" data-tweet=\"$SARTF $SARTF $PKI - Softer outlook from Sartorius pressures lab products makers https://seekingalpha.com/news/3301526-softer-outlook-from-sartorius-pressures-lab-products-makers?source=tweet\" data-url=\"https://seekingalpha.com/news/3301526-softer-outlook-from-sartorius-pressures-lab-products-makers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301521\" data-ts=\"1508252712\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RXDX\" target=\"_blank\">RXDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301521-ignytas-entrectinib-priority-medicine-in-europe-for-ntrk-fusion-positive-solid-tumors-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ignyta&#39;s entrectinib a Priority Medicine in Europe for NTRK Fusion-positive solid tumors; shares ahead 5%</a></h4><ul><li>Ignyta (<a href='https://seekingalpha.com/symbol/RXDX' title='Ignyta, Inc.'>RXDX</a> <font color='green'>+5.2%</font>) is up on below-average volume on the heels of its <a href=\"https://seekingalpha.com/pr/16970100-ignyta-receives-european-medicines-agency-prime-designation-entrectinib-ntrk-fusion-positive\" target=\"_blank\">announcement </a>that the European Medicines Agency &#40;EMA&#41; has designated entrectinib a Priority Medicine &#40;PRIME&#41;&nbsp;for the treatment of NTRK-positive, locally advanced/metastatic solid tumors in adult and pediatric patients who have either progressed following prior therapies or who have no acceptable therapeutic options.</li><li>PRIME status provides for enhanced EMA support and accelerated review of the marketing application. It is akin to the FDA's Breakthrough Therapy designation.</li><li><a href=\"http://ignyta.com/entrectinib-trk-inhibitor/\" target=\"_blank\">Entrectinib</a>, a selective tyrosine kinase inhibitor, is being developed for the treatment of a variety of tumor types.&nbsp;<a href=\"https://en.wikipedia.org/wiki/Tyrosine_kinase\" target=\"_blank\">Tyrosine kinase</a>&nbsp;is an enzyme that serves as an \"on/off\" switch in many cellular functions. If stuck \"on\" unregulated cell growth occurs.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301521\" data-linked=\"Ignyta&#39;s entrectinib a Priority Medicine in Europe for NTRK Fusion-positive solid tumors; shares ahead 5%\" data-tweet=\"$RXDX - Ignyta&#39;s entrectinib a Priority Medicine in Europe for NTRK Fusion-positive solid tumors; shares ahead 5% https://seekingalpha.com/news/3301521-ignytas-entrectinib-priority-medicine-in-europe-for-ntrk-fusion-positive-solid-tumors-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3301521-ignytas-entrectinib-priority-medicine-in-europe-for-ntrk-fusion-positive-solid-tumors-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301499\" data-ts=\"1508252447\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301499-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a> <font color='green'>+60%</font>. <a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+32%</font>. <a href='https://seekingalpha.com/symbol/VYGR' title='Voyager Therapeutics'>VYGR</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/RARX' title='Ra Pharmaceuticals'>RARX</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> IPXL <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/VICL' title='Vical Incorporated'>VICL</a> <font color='red'>-11%</font>. PBMD <font color='red'>-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301499\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$TRXC $DFFN $VYGR - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3301499-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3301499-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301512\" data-ts=\"1508251082\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301512-micron-moves-lower-clsa-sees-accelerating-dram-supply-in-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron moves lower as CLSA sees accelerating DRAM supply in 2018</a></h4><ul>     <li>Micron Technology (<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a> <font color='red'>-1.1%</font>) is lower after CLSA downgrades SK Hynix (<a href='https://seekingalpha.com/symbol/HXSCF' title='SK Hynix, Inc.'>OTC:HXSCF</a>) to Underperform, citing the <a href=\"https://www.streetinsider.com/Analyst+Comments/Micron+Technology+%28MU%29+Lower+as+CLSA+Sees+Acceleration+in+DRAM+Supply+in+2018/13395936.html\" target=\"_blank\">rising likelihood of new DRAM supply additions</a> in 2018.</li>     <li>CLSA says Samsung Electronics (<a href='https://seekingalpha.com/symbol/SSNLF' title='Samsung Electronics Co., Ltd.'>OTC:SSNLF</a>) will add 30K wpm in DRAM capacity at Line 16 in Q2 2018, and its recent checks indicate a high possibility of 100K-120K wpm DRAM capacity to be added in stages on the second floor of the  Pyeongtek fab from Q2.</li>     <li>The firm says the move could cause Hynix/Micron, with 30K-50K wpm cleanroom space, to consider expansion plans in addition to planned capacity additions by Samsung and Hynix in 2019.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301512\" data-linked=\"Micron moves lower as CLSA sees accelerating DRAM supply in 2018\" data-tweet=\"$MU $MU $HXSCF - Micron moves lower as CLSA sees accelerating DRAM supply in 2018 https://seekingalpha.com/news/3301512-micron-moves-lower-clsa-sees-accelerating-dram-supply-in-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3301512-micron-moves-lower-clsa-sees-accelerating-dram-supply-in-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>86&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301511\" data-ts=\"1508250980\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGN\" target=\"_blank\">AGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301511-ubs-softens-outlook-on-allergan-after-adverse-restasis-patent-ruling-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UBS softens outlook on Allergan after adverse Restasis patent ruling; shares up 1%</a></h4><ul><li>UBS has lowered its price target on Allergan (<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color='green'>+0.7%</font>) to $255 (28% upside) from $275 after the ruling by a Texas district court invalidating patients covering dry eye med RESTASIS. The revised outlook assumes the entry of generic competitors in early 2019 instead of 2024.</li><li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301249-u-s-court-invalidates-allergans-restasis-patents-shares-5-percent\" target=\"_blank\">U.S. court invalidates Allergan's Restasis patents; shares down 5%</a> (Oct. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301511\" data-linked=\"UBS softens outlook on Allergan after adverse Restasis patent ruling; shares up 1%\" data-tweet=\"$AGN - UBS softens outlook on Allergan after adverse Restasis patent ruling; shares up 1% https://seekingalpha.com/news/3301511-ubs-softens-outlook-on-allergan-after-adverse-restasis-patent-ruling-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3301511-ubs-softens-outlook-on-allergan-after-adverse-restasis-patent-ruling-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301510\" data-ts=\"1508250582\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QDEL\" target=\"_blank\">QDEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301510-fda-oks-quidels-rsv-hmpv-assay-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Quidel&#39;s RSV + hMPV assay; shares up 1%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16970420-quidel-receives-fda-clearance-solana-rsv-hmpv-assay\" target=\"_blank\">grants </a>510(k) clearance for Quidel's (<a href='https://seekingalpha.com/symbol/QDEL' title='Quidel Corporation'>QDEL</a> <font color='green'>+0.6%</font>) Solana RSV + hMPV assay for the detection of nucleic acids isolated from nasal and nasopharyngeal swabs to aid in the diagnosis of infections from respiratory syncytial virus &#40;RSV&#41; and/or human metapneumovirus (hMPV). The test, performed on the company's automated Solana instrument, can generate a result in 45 minutes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301510\" data-linked=\"FDA OKs Quidel&#39;s RSV + hMPV assay; shares up 1%\" data-tweet=\"$QDEL - FDA OKs Quidel&#39;s RSV + hMPV assay; shares up 1% https://seekingalpha.com/news/3301510-fda-oks-quidels-rsv-hmpv-assay-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3301510-fda-oks-quidels-rsv-hmpv-assay-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301509\" data-ts=\"1508250528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GS\" target=\"_blank\">GS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301509-morgan-stanley-up-goldman-down-after-top-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley up, Goldman down after each top estimates</a></h4><ul><li>Goldman Sachs (<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a> <font color='red'>-0.7%</font>) beat earnings expectations by a mile <a href=\"https://seekingalpha.com/news/3301418-goldman-sachs-1-percent-premarket-earnings-beat\" target=\"_blank\">as gains from private equity investments</a> (equity securities revenue jumped 51% Y/Y) helped offset continuing weak trading results. Investment banking revenue was also a bright spot, but backlogs did fall from both last quarter and a year ago.</li><li>As shops like Blackstone and KKR are well aware, <a href=\"https://www.bloomberg.com/gadfly/articles/2017-10-17/morgan-stanley-gets-win-in-wall-street-faceoff-with-goldman-sachs\" target=\"_blank\">writes Gillian Tan</a>, income from P-E investments can be rather lumpy. Investment banking isn't terribly predictable either, and the dip in backlogs may not bode well.</li><li>Meanwhile, <a href=\"https://seekingalpha.com/news/3301405-morgan-stanley-1-percent-earnings-topper\" target=\"_blank\">it's slow and steady</a> at Morgan Stanley (<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a> <font color='green'>+2%</font>) and its wealth management franchise (pretax income up 22% Y/Y, with asset management fees up about 15%).</li><li>In other news, Goldman finally discloses what was approved at last Spring's CCAR - $8.7B in buybacks and a nickel hike in the quarterly dividend for next year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301509\" data-linked=\"Morgan Stanley up, Goldman down after each top estimates\" data-tweet=\"$GS $GS $MS - Morgan Stanley up, Goldman down after each top estimates https://seekingalpha.com/news/3301509-morgan-stanley-up-goldman-down-after-top-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3301509-morgan-stanley-up-goldman-down-after-top-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301508\" data-ts=\"1508250370\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRPN\" target=\"_blank\">GRPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301508-grouponplus-1_7-gabelli-starts-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Groupon +1.7% as Gabelli starts at Buy</a></h4><ul>   <li>Groupon (NASDAQ:<a href='https://seekingalpha.com/symbol/GRPN' title='Groupon, Inc.'>GRPN</a>) is building a second day of gains, <font color='green'>up 1.7%</font> after Gabelli &amp; Co. launched coverage at Buy.</li>    <li>The firm has a $7 price target, implying 46% upside from current price.</li>    <li>Sentiment overall is mixed, with most firms rating the stock a Hold, and with four firms rating Sell. Yesterday, Cowen <a href=\"https://seekingalpha.com/news/3301156-groupon-plus-2_4-percent-cowen-takes-sell-sign\" target=\"_blank\">pulled its Sell rating</a> and boosted to Market Perform with an eye toward \"balanced expectations\" for the second half.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301508\" data-linked=\"Groupon +1.7% as Gabelli starts at Buy\" data-tweet=\"$GRPN - Groupon +1.7% as Gabelli starts at Buy https://seekingalpha.com/news/3301508-grouponplus-1_7-gabelli-starts-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3301508-grouponplus-1_7-gabelli-starts-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301504\" data-ts=\"1508249763\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRI\" target=\"_blank\">DRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301504-argus-lowers-expectations-on-darden-restaurants\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Argus lowers expectations on Darden Restaurants</a></h4><ul> <li>Argus lowers Darden Restaurants (NYSE:<a href='https://seekingalpha.com/symbol/DRI' title='Darden Restaurants, Inc.'>DRI</a>) to a Hold rating from Buy.</li> <li>\"Although we have a favorable view of Darden's strong brands, everyday value menu, and high customer satisfaction ratings, we do not believe that the company is immune to weak conditions in the casual-dining industry,\" reads the analyst note.</li> <li>The firm also points to a slowing trend of takeout orders at Olive Garden.</li> <li>Argues expects Darden to report FY18 EPS of $4.44 and FY19 EPS of $4.80, both marks are a downward revision.</li> <li>Shares of Darden are <font color='green'>up 0.36%</font> on the day, recovering from an early dip.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3301504\" data-linked=\"Argus lowers expectations on Darden Restaurants\" data-tweet=\"$DRI - Argus lowers expectations on Darden Restaurants https://seekingalpha.com/news/3301504-argus-lowers-expectations-on-darden-restaurants?source=tweet\" data-url=\"https://seekingalpha.com/news/3301504-argus-lowers-expectations-on-darden-restaurants\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301493\" data-ts=\"1508248531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIVE\" target=\"_blank\">HIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301493-aerohiveplus-4_3-craig-hallum-launches-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aerohive +4.3% as Craig-Hallum launches at Buy</a></h4><ul>   <li>Aerohive (NYSE:<a href='https://seekingalpha.com/symbol/HIVE' title='Aerohive Networks, Inc.'>HIVE</a>) is <font color='green'>up 4.3%</font> and wiping out a few days of declines after Craig-Hallum initiated it at Buy.</li>    <li>The firm set a price target of $6, implying 47% upside from this morning's higher price.</li>    <li>Since a decline after earnings on Aug. 2, shares are <font color='green'>up 30.8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301493\" data-linked=\"Aerohive +4.3% as Craig-Hallum launches at Buy\" data-tweet=\"$HIVE - Aerohive +4.3% as Craig-Hallum launches at Buy https://seekingalpha.com/news/3301493-aerohiveplus-4_3-craig-hallum-launches-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3301493-aerohiveplus-4_3-craig-hallum-launches-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301490\" data-ts=\"1508248340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LULU\" target=\"_blank\">LULU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301490-lululemon-expects-alibaba-boost-lands-on-hedgeyes-radar\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lululemon expects Alibaba boost, lands on Hedgeye&#39;s radar</a></h4><ul> <li>Lululemon's (<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a> <font color='green'>+1%</font>)&nbsp;relationship with Alibaba continues to be a bigger part of the retailer's <a href=\"https://www.cnbc.com/2017/10/16/amazon-isnt-playing-in-our-sandbox-lululemon-ceo-laurent-potdevin.html\" target=\"_blank\">overall strategy</a>. Management doesn't see the platform as hurting its positioning on the high end of the market.   </li> <li>\"There is really a passion for data, but not so much for the brands competing among themselves. So that relationship is really powerful and it translates to what we do offline both in our stores and through events,\" notes CEO Laurent Potdevin.</li> <li>Potdevin also issued his first analysis on reports of Amazon starting a sporswear apparel brand. \"I think Amazon is mostly around commodity product. That's not our sandbox,\" he observed.</li> <li>Shares of Lululemom perked up in morning trading today after Hedgeye named it a new long and called out 40% upside for shares.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301490\" data-linked=\"Lululemon expects Alibaba boost, lands on Hedgeye&#39;s radar\" data-tweet=\"$LULU - Lululemon expects Alibaba boost, lands on Hedgeye&#39;s radar https://seekingalpha.com/news/3301490-lululemon-expects-alibaba-boost-lands-on-hedgeyes-radar?source=tweet\" data-url=\"https://seekingalpha.com/news/3301490-lululemon-expects-alibaba-boost-lands-on-hedgeyes-radar\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301488\" data-ts=\"1508247871\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDXG\" target=\"_blank\">MDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301488-mimedx-on-go-mid-stage-study-of-amniofix-in-oak-shares-ahead-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MiMedx on go with mid-stage study of AmnioFix in OAK; shares ahead 3%</a></h4><ul><li>MiMedx (<a href='https://seekingalpha.com/symbol/MDXG' title='MiMedx Group Inc.'>OTC:MDXG</a> <font color='green'>+3%</font>) perks up in early trading in response to its <a href=\"https://seekingalpha.com/pr/16970177-mimedx-notified-fda-can-proceed-phase-2b-investigational-new-drug-clinical-trial\" target=\"_blank\">announcement </a>that the FDA has signed off on its Phase 2b clinical trial assessing AmnioFix Injectable (micronized dehydrated Human Chorion Membrane) for the treatment of osteoarthritis of the knee &#40;OAK&#41;.</li><li>The 318-subject study, expected to start in Q1, will compare AmnioFix to placebo. The primary endpoint will be change from baseline to day 90 in two scales called VAS and WOMAC.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301488\" data-linked=\"MiMedx on go with mid-stage study of AmnioFix in OAK; shares ahead 3%\" data-tweet=\"$MDXG - MiMedx on go with mid-stage study of AmnioFix in OAK; shares ahead 3% https://seekingalpha.com/news/3301488-mimedx-on-go-mid-stage-study-of-amniofix-in-oak-shares-ahead-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3301488-mimedx-on-go-mid-stage-study-of-amniofix-in-oak-shares-ahead-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301487\" data-ts=\"1508247561\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BUFF\" target=\"_blank\">BUFF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301487-blue-buffalo-falls-after-jpmorgan-downgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blue Buffalo falls after JPMorgan downgrades</a></h4><ul> <li>JPMorgan lowers Blue Buffalo Pet Products (<a href='https://seekingalpha.com/symbol/BUFF' title='Blue Buffalo'>BUFF</a> <font color='red'>-3.3%</font>) to a Neutral rating after having shares rated at Overweight.</li> <li>The firm is still positive on the long-term growth story, but sees some stumbles ahead in upcoming quarters.</li> <li>JP's price target on Blue Buffalo is trimmed by a buck to $31.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301487\" data-linked=\"Blue Buffalo falls after JPMorgan downgrades\" data-tweet=\"$BUFF - Blue Buffalo falls after JPMorgan downgrades https://seekingalpha.com/news/3301487-blue-buffalo-falls-after-jpmorgan-downgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3301487-blue-buffalo-falls-after-jpmorgan-downgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301486\" data-ts=\"1508247308\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATRO\" target=\"_blank\">ATRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301486-astronics-wins-contracts-from-several-major-north-american-airlines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Astronics wins contracts from several major North American airlines</a></h4><ul>     <li>Astronics (<a href='https://seekingalpha.com/symbol/ATRO' title='Astronics Corporation'>ATRO</a> <font color='green'>+4.7%</font>) shoots higher at the open on news that it was recently <a href=\"https://seekingalpha.com/pr/16969742-astronics-awarded-empower-seat-passenger-power-contracts-several-major-north-american\" target=\"_blank\">selected by six major North American airlines</a> to install its EmPOWER in-seat power systems on as many as 1,400 narrow-body and regional jet aircraft.</li>     <li>ATRO says it will equip  the airplanes with 110VAC and high output USB power for every passenger from \"nose to tail,\" including cabin crew stations; line-fit and retrofit installations will occur from early 2018 through 2023.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301486\" data-linked=\"Astronics wins contracts from several major North American airlines\" data-tweet=\"$ATRO - Astronics wins contracts from several major North American airlines https://seekingalpha.com/news/3301486-astronics-wins-contracts-from-several-major-north-american-airlines?source=tweet\" data-url=\"https://seekingalpha.com/news/3301486-astronics-wins-contracts-from-several-major-north-american-airlines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301483\" data-ts=\"1508247047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VERI\" target=\"_blank\">VERI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301483-veritone-looking-to-equity-market-to-gain-funds-for-acquisitions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veritone looking to equity market to gain funds for acquisitions</a></h4><ul>   <li>Veritone (NASDAQ:<a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a>) is <font color='red'>off 2%</font> premarket following news the company's considering <a href=\"https://timesofindia.indiatimes.com/business/international-business/veritone-ceo-expects-to-tap-equity-market-for-funds-in-2018/articleshow/61117587.cms\" target=\"_blank\">hitting up the equity market for more funds</a> for acquisitions in the coming year.</li>    <li>CEO Chad Steelberg tells Reuters that the company doesn't have immediate plans but that it's looking for several options from the public and private equity market.</li>    <li>\"We anticipate making several acquisitions and integrating them and we will be back in the capital market to continue to fund the company on its next stage of growth,\" he said, noting that the primary reason the company went public was to gain currency for acquisitions.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301483\" data-linked=\"Veritone looking to equity market to gain funds for acquisitions\" data-tweet=\"$VERI - Veritone looking to equity market to gain funds for acquisitions https://seekingalpha.com/news/3301483-veritone-looking-to-equity-market-to-gain-funds-for-acquisitions?source=tweet\" data-url=\"https://seekingalpha.com/news/3301483-veritone-looking-to-equity-market-to-gain-funds-for-acquisitions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301482\" data-ts=\"1508246887\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EMR\" target=\"_blank\">EMR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301482-emerson-upgrades-send-stock-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Emerson upgrades send the stock higher</a></h4><ul><li>Emerson (NYSE:<a href='https://seekingalpha.com/symbol/EMR' title='Emerson Electric Co.'>EMR</a>) <font color='green'>+1.6%</font> premarket after Cowen <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Cowen+Upgrades+Emerson+%28EMR%29+to+Outperform%2C+attributes+of+the+longstanding+EMR+bear+thesis+are+invalid/13395260.html\" target=\"_blank\">raised</a> the stock to Outperform from Market Perform, stating the \"attributes of the longstanding EMR bear thesis are invalid.\"</li><li>BofA also upgraded the stock to Buy from Neutral and increased its PT to $79 from $69. The firm feels shares should trade at a premium relative to peers given strong margins and returns, and accelerating earnings growth.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301482\" data-linked=\"Emerson upgrades send the stock higher\" data-tweet=\"$EMR - Emerson upgrades send the stock higher https://seekingalpha.com/news/3301482-emerson-upgrades-send-stock-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3301482-emerson-upgrades-send-stock-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301481\" data-ts=\"1508246796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DFFN\" target=\"_blank\">DFFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301481-fda-signs-off-on-phase-3-protocol-for-diffusion-pharmas-lead-candidate-tsc-shares-ahead-75\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA signs off on Phase 3 protocol for Diffusion Pharma&#39;s lead candidate TSC; shares ahead 75% premarket</a></h4><ul><li>Thinly traded nano cap Diffusion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a>) is up&nbsp;<font color='green'>75%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16970184-diffusion-pharmaceuticals-receives-final-fda-protocol-guidance-phase-3-clinical-trial-tsc\" target=\"_blank\">announcement </a>that it received protocol guidance from the FDA regarding its planned Phase 3 clinical trial assessing lead candidate trans sodium crocetinate &#40;TSC&#41; for newly diagnosed patients with inoperable glioblastoma multiforme &#40;GBM&#41;. The study will commence this quarter.</li><li>The 236-subject trial will compare two-year survival in patients receiving TSC + chemo and radiation (standard of care treatment) compared to chemo and radiation alone. Secondary endpoints include progression-free survival, objective response rate and quality of life measures.</li><li>Orphan Drug-tagged TSC is a small molecule that modifies the tumor microenvironment which improves the effectiveness of radiation therapy and chemotherapy.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253957-diffusion-pharma-60-percent-new-patent-covering-lead-product-candidate-tsc\" target=\"_blank\">Diffusion Pharma up 60% on new patent covering lead product candidate TSC</a> (March 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301481\" data-linked=\"FDA signs off on Phase 3 protocol for Diffusion Pharma&#39;s lead candidate TSC; shares ahead 75% premarket\" data-tweet=\"$DFFN - FDA signs off on Phase 3 protocol for Diffusion Pharma&#39;s lead candidate TSC; shares ahead 75% premarket https://seekingalpha.com/news/3301481-fda-signs-off-on-phase-3-protocol-for-diffusion-pharmas-lead-candidate-tsc-shares-ahead-75?source=tweet\" data-url=\"https://seekingalpha.com/news/3301481-fda-signs-off-on-phase-3-protocol-for-diffusion-pharmas-lead-candidate-tsc-shares-ahead-75\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301480\" data-ts=\"1508246611\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMC\" target=\"_blank\">OMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301480-omnicomplus-2_9-profits-organic-revenues-climb-in-q3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Omnicom +2.9% as profits, organic revenues climb in Q3</a></h4><ul>   <li>Omnicom (NYSE:<a href='https://seekingalpha.com/symbol/OMC' title='Omnicom Group Inc.'>OMC</a>) is <font color='green'>up 2.9%</font> premarket after its <a href=\"https://seekingalpha.com/news/3301386-omnicom-beats-0_03-beats-revenue\" target=\"_blank\">Q3 earnings</a> beat expectations with profits that grew despite sales that dipped with no help from acquisition revenues.</li>    <li>EPS rose 6.6% and beat consensus, while revenues fell 1.9% even with a positive foreign exchange impact and organic growth of 2.8%. Acquisition revenue (net of disposition revenue) fell 5.7%.</li>    <li>Net income rose 3.9% to $263.6M.</li>    <li>Regionally, revenue growth was 2.1% in North America and 3.8% in the UK, along with 7.8% in Euro Markets/Other Europe, 1.4% in Asia Pacific, -5.4% in Latin America and -1.6% in Middle East/Africa.</li>    <li>By discipline: Advertising +4.7%; CRM +0.1%; Public relations -0.4%; Specialty communications +5.1%.</li>    <li><a href=\"https://seekingalpha.com/pr/16970056-omnicom-group-reports-third-quarter-year-date-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3301480\" data-linked=\"Omnicom +2.9% as profits, organic revenues climb in Q3\" data-tweet=\"$OMC - Omnicom +2.9% as profits, organic revenues climb in Q3 https://seekingalpha.com/news/3301480-omnicomplus-2_9-profits-organic-revenues-climb-in-q3?source=tweet\" data-url=\"https://seekingalpha.com/news/3301480-omnicomplus-2_9-profits-organic-revenues-climb-in-q3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301479\" data-ts=\"1508246397\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNFI\" target=\"_blank\">UNFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301479-united-natural-foods-falls-after-rbc-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United Natural Foods falls after RBC downgrade</a></h4><ul> <li>Shares of United Natural Foods (NYSE:<a href='https://seekingalpha.com/symbol/UNFI' title='United Natural Foods, Inc.'>UNFI</a>)&nbsp;swing lower in premarket trading after RBC Capital Markets lowers its <a href=\"https://twitter.com/Briefingcom/status/920236308248780800\" target=\"_blank\">rating</a> to Underperform from Sector Perform.</li> <li>The investment firm sees a Whole Foods risk with the food stock based off its observation that the company isn't involved with many of the new initiatives from the Amazon property.</li> <li>RBC chips away at the price target on United Natural Foods to take it to $34.</li> <li>UNFI <font color='red'>-2.39%</font> premarket to $39.60.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301479\" data-linked=\"United Natural Foods falls after RBC downgrade\" data-tweet=\"$UNFI - United Natural Foods falls after RBC downgrade https://seekingalpha.com/news/3301479-united-natural-foods-falls-after-rbc-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3301479-united-natural-foods-falls-after-rbc-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301476\" data-ts=\"1508246311\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRV\" target=\"_blank\">CTRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301476-contravir-pharma-teams-up-canada-based-research-institute-to-advance-hbv-candidates-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ContraVir Pharma teams up with Canada-based research institute to advance HBV candidates; shares ahead 8% preamarket</a></h4><ul><li>Nano cap ContraVir Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a>) is up&nbsp;<font color='green'>8%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16970025-contravir-pharmaceuticals-announces-research-collaboration-agreement-li-ka-shing-institute\" target=\"_blank\">announced collaboration</a> with the Li Ka Shing Institute of Virology aimed at exploring the mechanisms of action of HBV candidates CRV431 and TXL.</li><li>The Alberta, Canada-based research institute is home to 37 principal investigators focused on the development of viral vaccines and antiviral therapies.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301476\" data-linked=\"ContraVir Pharma teams up with Canada-based research institute to advance HBV candidates; shares ahead 8% preamarket\" data-tweet=\"$CTRV $HEPA - ContraVir Pharma teams up with Canada-based research institute to advance HBV candidates; shares ahead 8% preamarket https://seekingalpha.com/news/3301476-contravir-pharma-teams-up-canada-based-research-institute-to-advance-hbv-candidates-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3301476-contravir-pharma-teams-up-canada-based-research-institute-to-advance-hbv-candidates-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301473\" data-ts=\"1508246048\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301473-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+66%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16970184-diffusion-pharmaceuticals-receives-final-fda-protocol-guidance-phase-3-clinical-trial-tsc\" target=\"_blank\">receiving</a> final protocol guidance from the U.S. Food and Drug Administration.</li><li><a href='https://seekingalpha.com/symbol/TGP' title='Teekay LNG Partners L.P.'>TGP</a> <font color='green'>+35%</font>.</li><li><a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a> <font color='green'>+11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3301443-synchronoss-sell-intralinks-unit-siris-capital-1b-shares-12-percent-premarket\" target=\"_blank\">selling</a> Intralinks unit to Siris Capital for $1B.</li><li><a href='https://seekingalpha.com/symbol/EYES' title='Second Sight Medical Products'>EYES</a> <font color='green'>+10%</font>&nbsp;on the <a href=\"https://seekingalpha.com/news/3301463-second-sight-go-germany-launch-argus-ii-study-rp-patients-sight-shares-26-percent-premarket\" target=\"_blank\">launch</a> of Argus II study in RP patients with sight in Germany.</li><li><a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a> <font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3301469-fda-ok-transenterixs-senhance-triggers-accelerated-expiration-series-warrants-shares-6\" target=\"_blank\">accelerated</a> expiration of Series A Warrants.</li><li>BIOP <font color='green'>+8%</font>.</li><li><a href='https://seekingalpha.com/symbol/SAVE' title='Spirit Airlines'>SAVE</a> <font color='green'>+7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3301462-spirit-airlines-rallies-lifting-unit-revenue-guidance\" target=\"_blank\">raising</a> unit revenue guidance.</li><li><a href='https://seekingalpha.com/symbol/ROSG-OLD' title='Rosetta Genomics Ltd.'>ROSG-OLD</a> <font color='green'>+7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301473\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$DFFN $TGP $SNCR - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3301473-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3301473-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301470\" data-ts=\"1508245864\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301470-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/BMI' title='Badger Meter, Inc.'>BMI</a>&nbsp;<font color='red'>-18%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3301299-badger-meter-misses-0_08-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>IPXL&nbsp;<font color='red'>-11%</font>&nbsp;on Amneal Pharma <a href=\"https://seekingalpha.com/news/3301441-impax-labs-9-percent-premarket-amneal-pharma-merger\" target=\"_blank\">merger</a>.</li><li><a href='https://seekingalpha.com/symbol/LBIX-OLD' title='Leading Brands Inc'>LBIX-OLD</a> <font color='red'>-10%</font>.</li><li><a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/RWLK' title='ReWalk Robotics'>RWLK</a>&nbsp;<font color='red'>-7%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16970200-rewalk-robotics-launches-public-offering-ordinary-shares\" target=\"_blank\">launching</a> public offering of ordinary shares.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3301470\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$BMI $AMRX $LBIX-OLD - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3301470-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3301470-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301469\" data-ts=\"1508245664\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRXC\" target=\"_blank\">TRXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301469-fda-ok-of-transenterixs-senhance-triggers-accelerated-expiration-of-series-warrants-shares-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OK of TransEnterix&#39;s Senhance triggers accelerated expiration of Series A Warrants; shares up 6% premarket</a></h4><ul><li>One-year Series A Warrants issued by TransEnterix (NYSEMKT:<a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a>) in its April equity offering will now expire at 11:59 pm ET on Tuesday, October 31. The accelerated timeline was <a href=\"https://www.sec.gov/Archives/edgar/data/876378/000129993317001044/exhibit1.htm\" target=\"_blank\">triggered </a>by the FDA's clearance of the Senhance Surgical Robotic System a few days ago.</li><li>The warrants will most certainly be tendered considering the $1 exercise price price. Shares closed yesterday at $2.81.</li><li>Shares are up&nbsp;<font color='green'>6%</font>&nbsp;premarket on robust volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301042-fda-clears-tranenterixs-robotic-surgery-system-senhance-shares-ahead-60-percent-hours\" target=\"_blank\">FDA clears TranEnterix's robotic surgery system Senhance; shares ahead 60% after hours</a> (Oct. 13)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3261289-transenterix-prices-equity-offering-shares-slip-17-percent-premarket\" target=\"_blank\">TransEnterix prices equity offering; shares slip 17% premarket</a> (April 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301469\" data-linked=\"FDA OK of TransEnterix&#39;s Senhance triggers accelerated expiration of Series A Warrants; shares up 6% premarket\" data-tweet=\"$TRXC - FDA OK of TransEnterix&#39;s Senhance triggers accelerated expiration of Series A Warrants; shares up 6% premarket https://seekingalpha.com/news/3301469-fda-ok-of-transenterixs-senhance-triggers-accelerated-expiration-of-series-warrants-shares-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3301469-fda-ok-of-transenterixs-senhance-triggers-accelerated-expiration-of-series-warrants-shares-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301463\" data-ts=\"1508244753\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYES\" target=\"_blank\">EYES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301463-second-sight-on-go-in-germany-to-launch-argus-ii-study-in-rp-patients-sight-shares-up-26\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Second Sight on go in Germany to launch Argus II study in RP patients with sight; shares up 26% premarket</a></h4><ul><li>Thinly traded nano cap Second Sight Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/EYES' title='Second Sight Medical Products'>EYES</a>) is up&nbsp;<font color='green'>26%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16970073-second-sight-receives-approval-bundesinstitut-fur-arzneimittel-und-medizinprodukte-germany\" target=\"_blank\">announcement </a>that German regulators have signed off on a 10-subject study assessing the Argus II Retinal Prosthesis System in retinitis pigmentosa &#40;RP&#41;&nbsp;patients who have some sight (tunnel vision).</li><li>The company says the targeted population will increase the potential market for Argus by as much as 3x.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301463\" data-linked=\"Second Sight on go in Germany to launch Argus II study in RP patients with sight; shares up 26% premarket\" data-tweet=\"$EYES - Second Sight on go in Germany to launch Argus II study in RP patients with sight; shares up 26% premarket https://seekingalpha.com/news/3301463-second-sight-on-go-in-germany-to-launch-argus-ii-study-in-rp-patients-sight-shares-up-26?source=tweet\" data-url=\"https://seekingalpha.com/news/3301463-second-sight-on-go-in-germany-to-launch-argus-ii-study-in-rp-patients-sight-shares-up-26\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301462\" data-ts=\"1508244751\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAVE\" target=\"_blank\">SAVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301462-spirit-airlines-rallies-after-lifting-unit-revenue-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spirit Airlines rallies after lifting unit revenue guidance</a></h4><ul> <li>Spirit Airlines (NASDAQ:<a href='https://seekingalpha.com/symbol/SAVE' title='Spirit Airlines'>SAVE</a>) estimates that revenue per available seat mile fell 6.5% in Q3 to top the prior guidance for a drop of 7.0% to 8.5%.</li> <li>The carrier cites an improved load factor and better ticket yields for the quarter.</li> <li><a href=\"https://seekingalpha.com/filing/3728942\" target=\"_blank\">SEC Form 8-K</a></li> <li>Shares of Spirit are <font color='green'>up 10.01%</font> in premarket trading to $36.82.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301462\" data-linked=\"Spirit Airlines rallies after lifting unit revenue guidance\" data-tweet=\"$SAVE - Spirit Airlines rallies after lifting unit revenue guidance https://seekingalpha.com/news/3301462-spirit-airlines-rallies-after-lifting-unit-revenue-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3301462-spirit-airlines-rallies-after-lifting-unit-revenue-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301459\" data-ts=\"1508244216\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301459-valeants-b-l-to-launch-next-gen-intraocular-lens-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valeant&#39;s B+L to launch next-gen intraocular lens; shares up 1% premarket</a></h4><ul><li>Valeant Pharmaceuticals (VRX) unit Bausch + Lomb <a href=\"http://www.bausch.com/our-company/recent-news/id/2383/10162017-monday\" target=\"_blank\">introduces </a>its next-generation hydrophobic acrylic intraocular lens, enVista MX60E with StableFlex technology.</li><li>The company says its Sharp edge design reduces posterior capsular opacification (becoming opaque) compared to round edge designs. It also features AccuSet haptics which helps secure the lens in position via its offset design and broad contact angle.</li><li>Market launch will commence in Q1.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301459\" data-linked=\"Valeant&#39;s B+L to launch next-gen intraocular lens; shares up 1% premarket\" data-tweet=\"$BHC - Valeant&#39;s B+L to launch next-gen intraocular lens; shares up 1% premarket https://seekingalpha.com/news/3301459-valeants-b-l-to-launch-next-gen-intraocular-lens-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3301459-valeants-b-l-to-launch-next-gen-intraocular-lens-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>212&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301446\" data-ts=\"1508243622\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GWW\" target=\"_blank\">GWW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301446-w-w-graingers-positive-post-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">W.W. Grainger&#39;s positive post Q3 results</a></h4><ul>     <li>W.W. Grainger (NYSE:<a href='https://seekingalpha.com/symbol/GWW' title='W.W. Grainger, Inc.'>GWW</a>) reports sales rose 3% in <a href=\"https://seekingalpha.com/pr/16970249-grainger-reports-results-2017-third-quarter\" target=\"_blank\">Q3</a> on a daily basis, driven by 8 percentage points from volume.</li>     <li>U.S. business sales slipped 1% to $2.02B, driven by a 7 percentage point increase from volume and 1 percentage point from intercompany sales.</li>     <li>Canada business sales grew 5% to $188.22M.</li>     <li>Other businesses sales expanded 11% to $536.93M.</li>     <li>Gross margin rate fell 140 bps to 38.6%</li>     <li>Adjusted operating margin rate down 180 bps to 11%.</li>     <li><b>FY2017 Guidance</b>:&nbsp;Sales: +1.5% to +2.5%; Diluted EPS: $10.40 to $10.90; Tax rate: 34.5% to 35.5%.</li>     <li>GWW&nbsp;<font color='green'>+1.45%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301446\" data-linked=\"W.W. Grainger&#39;s positive post Q3 results\" data-tweet=\"$GWW - W.W. Grainger&#39;s positive post Q3 results https://seekingalpha.com/news/3301446-w-w-graingers-positive-post-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3301446-w-w-graingers-positive-post-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301448\" data-ts=\"1508243010\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQM\" target=\"_blank\">SQM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301448-sqm-chile-fail-to-resolve-lithium-contract-dispute\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SQM, Chile fail to resolve lithium contract dispute</a></h4><ul>     <li>Sociedad Quimica y Minera (NYSE:<a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a>) <font color='red'>-3.6%</font> premarket on news that talks to resolve a legal dispute with Chilean authorities have <a href=\"http://www.reuters.com/article/us-sqm-arbitration/talks-between-sqm-chile-authorities-end-with-no-deal-idUSKBN1CL31V\" target=\"_blank\">ended without reaching an agreement</a>.</li>     <li>Chile's state-run development agency Corfo has alleged that SQM has failed to meet contractual obligations in its lithium lease agreement with the government; the company says it has fully complied.</li>     <li>Arbitration has been ongoing since mid-2014, and a decision is expected by year's end.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301448\" data-linked=\"SQM, Chile fail to resolve lithium contract dispute\" data-tweet=\"$SQM - SQM, Chile fail to resolve lithium contract dispute https://seekingalpha.com/news/3301448-sqm-chile-fail-to-resolve-lithium-contract-dispute?source=tweet\" data-url=\"https://seekingalpha.com/news/3301448-sqm-chile-fail-to-resolve-lithium-contract-dispute\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301443\" data-ts=\"1508242746\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNCR\" target=\"_blank\">SNCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301443-synchronoss-to-sell-intralinks-unit-to-siris-capital-for-1b-shares-up-12-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synchronoss to sell Intralinks unit to Siris Capital for $1B; shares up 12% premarket</a></h4><ul><li>Concluding its strategic alternatives process,&nbsp;Synchronoss Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a>) is set to \"double down\" on its communications and media business, and sell non-core assets.</li><li>The company has agreed to a sale of Intralinks Holdings to Siris Capital for roughly $1B. SIris will also buy $185M of convertible preferred stock in SNCR that will initially be convertible into about 19.8% of&nbsp; SNCR common shares.</li><li>The sale of Intralinks is seen closing in the middle of next month. The preferred sale is expected to close in Q1 of 2018.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16970258-synchronoss-technologies-announces-successful-conclusion-strategic-alternatives-process\" target=\"_blank\">Press Release</a></li><li>Shares&nbsp;<font color='green'>+11.8%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3301443\" data-linked=\"Synchronoss to sell Intralinks unit to Siris Capital for $1B; shares up 12% premarket\" data-tweet=\"$SNCR - Synchronoss to sell Intralinks unit to Siris Capital for $1B; shares up 12% premarket https://seekingalpha.com/news/3301443-synchronoss-to-sell-intralinks-unit-to-siris-capital-for-1b-shares-up-12-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3301443-synchronoss-to-sell-intralinks-unit-to-siris-capital-for-1b-shares-up-12-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301441\" data-ts=\"1508242670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRX\" target=\"_blank\">AMRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301441-impax-labs-down-9-premarket-on-amneal-pharma-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Impax Labs down 9% premarket on Amneal Pharma merger</a></h4><ul><li>It's official. Impax Laboratories (IPXL) and privately held Amneal Pharmaceuticals LLC will <a href=\"https://seekingalpha.com/pr/16970178-amneal-impax-combine\" target=\"_blank\">merge </a>in an all-stock deal that will result in Amneal shareholders owning ~75% of the combined company, the fifth largest generic drugmaker by revenue in the U.S.</li><li>$200M in annual cost savings expected within three years. Accretive to Impax's non-GAAP EPS within the first 12 months. Pro forma non-GAAP EBITDA: $700M - 750M.</li><li>In connection with the transaction, Amneal Holdings members have entered into agreements with certain institutional investors to sell 46.8M unregistered common shares at $18.25 per share yielding gross proceeds of $855M.</li><li>The deal should close in H1 2018.</li><li><strong>Impax 2017 guidance</strong>: non-GAAP EPS: $0.55 - 0.70.</li><li>The companies will host a conference call this morning at 8:30 am ET to discuss the merger.</li><li>IPXL is off&nbsp;<font color='red'>9%</font>&nbsp;premarket on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301441\" data-linked=\"Impax Labs down 9% premarket on Amneal Pharma merger\" data-tweet=\"$AMRX - Impax Labs down 9% premarket on Amneal Pharma merger https://seekingalpha.com/news/3301441-impax-labs-down-9-premarket-on-amneal-pharma-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3301441-impax-labs-down-9-premarket-on-amneal-pharma-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301421\" data-ts=\"1508241419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNH\" target=\"_blank\">UNH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301421-unitedhealth-group-q3-revenues-up-9-non-gaap-eps-up-23-shares-ahead-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UnitedHealth Group Q3 revenues up 9%; non-GAAP EPS up 23%; shares ahead 1% premarket</a></h4><ul><li>UnitedHealth Group (<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a>) <a href=\"https://seekingalpha.com/pr/16969981-unitedhealth-group-third-quarter-highlights\" target=\"_blank\">Q3 results</a>: Revenues: $50,322M (+8.7%); Premiums: $39,552M (+9.4%); Products: $6,665M (-0.5%); Services: $3,858M (+18.2%); Investment and other income: $247M (+29.3%).</li><li>UnitedHealthcare: $40,734M (+9.6%); Optum: $22,885M (+8.4%).</li><li>Operating Income: $4,088M (+14.2%); Net Income: $2,485M (+26.3%); EPS: $2.51 (+23.6%); Non-GAAP EPS: $2.66 (+22.6%); Quick Assets: $19,794M (+49.1%); CF Ops: $16,173M (+44.4%).</li><li>The Company expects GAAP and Non-GAAP EPS to approach $9.45 and $10.00 respectively.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301421\" data-linked=\"UnitedHealth Group Q3 revenues up 9%; non-GAAP EPS up 23%; shares ahead 1% premarket\" data-tweet=\"$UNH - UnitedHealth Group Q3 revenues up 9%; non-GAAP EPS up 23%; shares ahead 1% premarket https://seekingalpha.com/news/3301421-unitedhealth-group-q3-revenues-up-9-non-gaap-eps-up-23-shares-ahead-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3301421-unitedhealth-group-q3-revenues-up-9-non-gaap-eps-up-23-shares-ahead-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301420\" data-ts=\"1508241318\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MET\" target=\"_blank\">MET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301420-prudential-up-1-after-citi-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Prudential up more than 1% after Citi upgrade</a></h4><ul><li>A notable bear on MetLife (NYSE:<a href='https://seekingalpha.com/symbol/MET' title='MetLife, Inc.'>MET</a>), Citi analyst Suneet Kamath says Prudential (NYSE:<a href='https://seekingalpha.com/symbol/PRU' title='Prudential Financial, Inc.'>PRU</a>) is more efficient with capital than MET and has more \"best-in-class\" business segments. His sum-of-the-parts analysis sees 8% upside for Prudential vs. 10% downside at MetLife.</li><li>He upgrades PRU to Buy from Neutral, with price target raised to $123 from $110. MetLife remains a Sell.</li><li>Source: Bloomberg's Lily Katz</li><li>PRU&nbsp;<font color='green'>+1.25%</font>&nbsp;premarket to $110.75.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301420\" data-linked=\"Prudential up more than 1% after Citi upgrade\" data-tweet=\"$MET $MET $PRU - Prudential up more than 1% after Citi upgrade https://seekingalpha.com/news/3301420-prudential-up-1-after-citi-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3301420-prudential-up-1-after-citi-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301418\" data-ts=\"1508240794\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GS\" target=\"_blank\">GS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301418-goldman-sachs-up-1-premarket-after-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs up 1% premarket after earnings beat</a></h4><ul><li>Q3 net earnings of $2.13B or $5.02 per share vs. $4.88 a year ago. Revenue up 2% Y/Y to $8.33B.</li><li>Investment Banking revenue up 17% Y/Y to $1.8B. Financial advisory revenue up 28% to $911M. Underwriting revenue flat at $886M. Investment banking backlog slips from Q2 and from one year ago.</li><li>Institutional Client Services revenue down 17% Y/Y to $3.12B. FICC revenue down 26% to $1.45B, but still topped estimates for $1.37B..</li><li>Investment &amp; Lending revenue up 35% Y/Y to $1.88B. Equity securities revenue up 51% to $1.39B.</li><li>Investment Management revenue up 3% Y/Y to $1.53B.</li><li>Compensation and benefits expense flat Y/Y at $3.17B. Comp and benefits ratio to revenues of 40% during first nine months of 2017 vs. 41% in 2016.</li><li>CET 1 ratio of 13.3% down 60 basis points during quarter. 9.6M shares repurchased during quarter for $2.17B. Tangible book value per share of $180.42.</li><li><a href=\"http://www.goldmansachs.com/investor-relations\" target=\"_blank\">Conference call at 9:30 ET</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3301410-goldman-sachs-beats-0_85-beats-revenue\" target=\"_blank\">Goldman Sachs beats by $0.85, beats on revenue</a> (Oct. 17)</li><li><a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a>&nbsp;<font color='green'>+1.1%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3301418\" data-linked=\"Goldman Sachs up 1% premarket after earnings beat\" data-tweet=\"$GS - Goldman Sachs up 1% premarket after earnings beat https://seekingalpha.com/news/3301418-goldman-sachs-up-1-premarket-after-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3301418-goldman-sachs-up-1-premarket-after-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301415\" data-ts=\"1508240645\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRX\" target=\"_blank\">AMRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301415-trading-halted-in-impax-labs-pending-news-of-merger-amneal-pharma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trading halted in Impax Labs pending news of merger with Amneal Pharma</a></h4><ul><li>Nasdaq has suspended trading in Impax Laboratories (IPXL) pending the release of news, specifically its merger with Amneal Pharmaceuticals.</li><li>Trading will resume at 8:00 am ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301350-wsj-impax-labs-amneal-pharma-near-merger-deal\" target=\"_blank\">WSJ: Impax Labs, Amneal Pharma near merger deal</a> (Oct. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301415\" data-linked=\"Trading halted in Impax Labs pending news of merger with Amneal Pharma\" data-tweet=\"$AMRX - Trading halted in Impax Labs pending news of merger with Amneal Pharma https://seekingalpha.com/news/3301415-trading-halted-in-impax-labs-pending-news-of-merger-amneal-pharma?source=tweet\" data-url=\"https://seekingalpha.com/news/3301415-trading-halted-in-impax-labs-pending-news-of-merger-amneal-pharma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301409\" data-ts=\"1508240296\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JNJ\" target=\"_blank\">JNJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301409-johnson-johnson-q3-revenues-up-10-non-gaap-eps-up-13-raises-2017-guidance-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Johnson &amp; Johnson Q3 revenues up 10%; non-GAAP EPS up 13%; raises 2017 guidance; shares ahead 2% premarket</a></h4><ul><li>Johnson &amp; Johnson (<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>) <a href=\"https://seekingalpha.com/pr/16970057-johnson-and-johnson-reports-2017-third-quarter-results\" target=\"_blank\">Q3 results</a>: Revenues: $19,650M (+10.3%); Consumer: $3,356M (+2.9%); Pharmaceutical: $9,695M (+15.4%); Medical Devices: $6,599M (+7.1%);</li><li>Net Income: $3,764M (-11.9%); EPS: $1.37 (-10.5%); Non-GAAP EPS: $1.90 (+13.1%).</li><li>Sales by Business: Baby Care: $477M (-3.6%); Beauty: $1,033M (+5.5%); Oral Care: $382M (-0.3%); Women's Health: $270M (+0.4%); Immunology: $3,269M (+6.0%); Infectious Diseases: $813M (-3.4%); Neuroscience: $1,498M (+2.3%); Oncology: $1,898M (+25.1%); Cardiovascular / Metabolism / Other: $1,547M (+3.6%).</li><li>Key Product Sales: REMICADE: $1647M (-7.6%); SIMPONI / SIMPONI ARIA: $476M (-1.0%); STELARA: $1,124M (+38.1%); DARZALEX: $317M (+94.5%); XARELTO: $635M (+20.0%); ZYTIGA: $669M (+14.9%).</li><li><strong>2017 Guidance</strong>: Revenues: $76.1B - $76.5B from $75.8B - 76.1B; Non-GAAP EPS: $7.25 - 7.30 from $7.12 - 7.22.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;premarket on modest volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301409\" data-linked=\"Johnson &amp; Johnson Q3 revenues up 10%; non-GAAP EPS up 13%; raises 2017 guidance; shares ahead 2% premarket\" data-tweet=\"$JNJ - Johnson &amp; Johnson Q3 revenues up 10%; non-GAAP EPS up 13%; raises 2017 guidance; shares ahead 2% premarket https://seekingalpha.com/news/3301409-johnson-johnson-q3-revenues-up-10-non-gaap-eps-up-13-raises-2017-guidance-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3301409-johnson-johnson-q3-revenues-up-10-non-gaap-eps-up-13-raises-2017-guidance-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301408\" data-ts=\"1508239961\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRAX\" target=\"_blank\">SRAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301408-social-reality-pursing-strategic-alternatives-for-sraxmd-business-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Social Reality pursing strategic alternatives for SRAXmd business; shares up 6%</a></h4><ul><li>A spinoff of the operation into its own public company, strategic acquisitions, or other transactions are under consideration.</li><li><a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a>&nbsp;<font color='green'>+6.3%</font>&nbsp;premarket</li><li>Source: <a href=\"https://seekingalpha.com/pr/16970153-social-reality-inc-pursue-strategic-alternatives-sraxmd-healthcare-business\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301408\" data-linked=\"Social Reality pursing strategic alternatives for SRAXmd business; shares up 6%\" data-tweet=\"$SRAX - Social Reality pursing strategic alternatives for SRAXmd business; shares up 6% https://seekingalpha.com/news/3301408-social-reality-pursing-strategic-alternatives-for-sraxmd-business-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3301408-social-reality-pursing-strategic-alternatives-for-sraxmd-business-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}